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Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is the 
current standard therapy for patients with high risk non-muscle-invasive 
bladder cancer (NMIBC). However, it has a significant failure rate which may 
result in disease progression and development of metastases. Apart from 
clinic-pathological factors, genetic polymorphisms have been suggested to 
predict BCG response.  
 
In the first part of the study, we determined the predictive value of 
NRAMP1 and hGPX1 gene polymorphisms for cancer recurrence and 
response to intravesical BCG, in a cohort of 99 high risk NMIBC patients, 
who were enrolled in a prospective randomized clinical trial comparing 
standard dose BCG, low dose BCG and low dose BCG plus interferon alpha 
2b. Patients’ DNA was extracted from peripheral blood samples, and analysed 
using restriction fragment length polymorphisms and DNA sequencing. The 
genotypic frequencies of patients were similar to that of normal population, 
represented by 85 healthy volunteers from whom peripheral blood DNA were 
obtained and analysed. We found that polymorphisms of the NRAMP1 
(D534N G:G genotype and presence of allele 3 in (GT)n genotypes) and 
hGPX1 (CT genotype) genes predicted for recurrence of bladder cancer after 
BCG immunotherapy. Patients having a combination of the poor risk 
genotypes were at risk of disease progression. Patients with these gene 






In second part of the study we investigated the effect of the mTOR 
inhibition on a panel of bladder cancer cells, in an effort to explore its use as a 
potential new therapeutic target for bladder cancer therapy. We found that the 
mTOR inhibitor RAD001 (everolimus) inhibited the growth of bladder cancer 
cells in vitro. This growth inhibition was dose dependent and transient in 
nature, which could be overcome by repeat dosing. We showed that mTOR 
inhibition resulted in G1 growth phase arrest after prolonged treatment in 
sensitive cell lines, cell death in the absence of apoptosis, changes in 
downstream signaling of p70S6K, and 4E-BP-1, and inhibition of protein 
synthesis. Using nude mice subcutaneously implanted with human bladder 
cancer cells, we also showed that RAD001 was effective in vivo, despite the 
heterogeneity of responses seen in vitro, in part because of changes in 
angiogenesis seen in some tumours.  
 
In the final part of the study, we showed that mTOR inhibition resulted 
in induction of autophagy and changes in oxidative stress response in some 
cell lines. We demonstrated that autophagic inhibitors could enhance the 
efficacy of RAD001and provide further understanding of the role of autophagy 
in bladder cancer. RAD001 was found to enhance the efficacy of common 
chemotherapeutic agents used in bladder cancer. Efficacy was maintained 
despite dose reduction of chemotherapy agents, when combined with 
RAD001. We also showed efficacy and downstream effects of silencing 
mTOR, using specific SiRNA on sensitive bladder cancer cells, as a prelude to 
investigating its future use intravesically for the treatment of NMIBC. Our 





cancer, and mTOR inhibition may have a future role in the treatment of 
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1.1. Bladder cancer  
1.1.1. Epidemiology of bladder cancer 
1.1.1.1. Overview 
The urothelial cancers are malignant tumours that arise from of the 
urothelium (which is lined by transitional cells) of the urinary tract. Cancer of 
the urinary bladder is the most common cancer of the urinary tract and more 
than 90% of bladder cancers are urothelial carcinomas. Bladder cancer is the 
7th most common cancer and 9th most common cause of death amongst men 
worldwide (Jemal, Bray et al. 2011). It was estimated that there were 386,300 
new cases and 150,200 deaths from bladder cancer that occurred in 2008 
worldwide (Jemal, Bray et al. 2011). In Singapore, it is the 10th most common 
cancer and constitutes 3% of all malignancies in males (2006-2010), with an 
age-standardized rate of 6.8 per 100,000 per year (Teo and Soo 2013). 
 
1.1.1.2. Global Burden and geographical variation 
Bladder cancer incidence is the highest in developed countries such as 
those in the southern and western parts of Europe and North America, where 
smoking and occupational exposures are the major risk factors (Jemal, Bray et 
al. 2011). Incidence rates are also high in other parts Europe, Northern Africa 
and Western Asia (Jemal, Bray et al. 2011). Incidence in the rest of Asia is 
only about 20-30% as high as in the United States (Jemal, Bray et al. 2011). 
The lowest incidence rates of bladder cancer are in the countries of Melanesia 
and Middle Africa (Jemal, Bray et al. 2011). In general, in Western countries, 
incidence rates have been rising, but the increase has slowed or stopped in 





highest in Egyptian males, but have stabilized in males and decreased in 
females in the United States from 1997 through 2006 (Jemal, Bray et al. 
2011). Declines have been observed in most countries in Europe since 
the1990s, due in part to reductions in smoking prevalence and reductions in 
occupational exposures (Jemal, Bray et al. 2011). Although mortality rates in 
most part of the world are decreasing, trends in developing countries tend to 
be more variable (Parkin 2008).  
 
1.1.1.3. Age, racial and gender variation 
The incidence rates of bladder cancer are generally three to four times 
higher in men than in women (Jemal, Siegel et al. 2008; Parkin 2008). Bladder 
cancer is usually diagnosed in the late middle and elderly ages, primarily 
affecting people between the ages of 50 and 75. The risk of developing 
bladder cancer increases dramatically with age. The incidence rates of invasive 
bladder cancer in men from birth to age 39 years, ages 40 to 59 years, ages 60 
to 69 years and ages 70 to 79 years are 0.02%, 0.41%, 0.96% and 3.5% 
respectively (Jemal, Siegel et al. 2008). The incidence rates of invasive 
bladder cancer in women from birth to age 39 years, ages 40 to 59 years, ages 
60 to 69 years and ages 70 to 79 years are 0.01%, 0.13%, 0.26% and 0.99% 
respectively (Jemal, Siegel et al. 2008). In the United States, whites have a 
higher incidence of bladder cancer compared to African-Americans in both 
males and females (Jemal, Siegel et al. 2008; Parkin 2008). In Singapore 
(2006 to 2010), Malay and Indian males have a slightly higher incidence of 





7.0 and 6.7 per 100,000 per year respectively (National Registry of Diseases 
Office 2010). 
 
1.1.1.4. Risk factors 
The exact causes of bladder cancer are yet unknown. Currently, many 
believe that the environment plays a primary role in the development of 
bladder cancer, while inherited factors may alter the phenotype and clinical 
presentation of the disease (Horikawa, Gu et al. 2008; Volanis, Kadiyska et al. 
2010). The most important environmental risk factors responsible for bladder 
cancer include cigarette smoking and exposure to industrial chemicals. The 
incidence of urothelial cancers has been shown to be approximately 4 times 
higher in smokers compared with non-smokers (Burch, Rohan et al. 1989). 
Zeegers et al reported in a large meta-analysis that current and former cigarette 
smokers had greater odds of developing bladder cancer compared to non-
smokers, with odds ratios of 3.33 (95% CI, 2.63– 4.21) and 1.98 (95% CI, 
1.72–2.29) respectively (Zeegers, Tan et al. 2000). In that meta-analysis, it 
was also estimated that about half of all bladder cancers in men and 30% in 
women are due in part to cigarette smoking. Similarly, cigar smoking, pipe 
smoking, and second-hand smoke have also been implicated as risk factors for 
urothelial cancers (Kiriluk, Prasad et al. 2012). While the association with 
cigarette smoking have been well defined, it remains unclear which 
carcinogens from tobacco smoke, whether alone or in combination, are mainly 
responsible for developing urothelial cancers (Kiriluk, Prasad et al. 2012). One 
of the most notable risk factor for the development of bladder cancers is 





Increased risk of bladder cancer, independent to that of smoking has been 
demonstrated in occupational cohort studies and meta-analyses, for individuals 
exposed to aromatic amines working in various industries including farming, 
chemical plants, hair dressing, rubber and textile industries (Dolin 1992; Viel 
and Challier 1995; Ward, Sabbioni et al. 1996; Takkouche, Regueira-Mendez 
et al. 2009; Carreon, Hein et al. 2010; Harling, Schablon et al. 2010; Pira, 
Piolatto et al. 2010). Long term exposure to the chemicals 1-naphthylamine, 2-
naphthylamine, benzidine, 4-aminobiphenyl, ortho-toluidine and chloroaniline 
(MOCA) has been suggested to act as mutagens that bind to DNA, resulting in 
bladder cancer development (Case, Hosker et al. 1954; Melick, Escue et al. 
1955; Swaminathan, Frederickson et al. 1996; Baan, Straif et al. 2008; 
Carreon, Hein et al. 2010; Pira, Piolatto et al. 2010). Characteristics of 
drinking water, including arsenic at concentrations more than 300 μg/l and 
trihalomethanes in chlorinated water have also been linked to bladder cancer 
development (Villanueva, Cantor et al. 2004; Navarro Silvera and Rohan 
2007; Meliker, Slotnick et al. 2010; Costet, Villanueva et al. 2011).  
 
Coffee, tea, alcohol, analgesic abuse and artificial sweeteners have all 
been studied as possible  risk factors for bladder cancer, but associations are 
weak or controversial (Kiriluk, Prasad et al. 2012). Increased risk of bladder 
cancer has been shown subsequent to the use of radiotherapy for the treatment 
of pelvic malignancies, including cervical, endometrial, and prostate cancer 
(Chaturvedi, Engels et al. 2007; Nieder, Porter et al. 2008; Brown, Neeley et 
al. 2010). This is likely due to the generation of radiation induced free radicals 





cyclophosphamide has been shown to cause bladder cancer (Levine and Richie 
1989). Chronic inflammation and infection of the bladder has been shown to 
be strongly associated with squamous cell carcinoma of the bladder, where the 
most widely known infectious agent to cause bladder cancer is the parasite 
Schistosoma haematobium (Kiriluk, Prasad et al. 2012). The role of chronic 
inflammation and the development of urothelial bladder cancers is less clear 
(Kiriluk, Prasad et al. 2012). Genetic factors such as polymorphisms in 
metabolic enzyme genes (N-acetyltransferase, glutathione-S-transferase, 
myeloperoxidase, and cytochrome P-450), DNA repair genes (xeroderma 
pigmentosumand x-ray repair cross-complementing genes), and others such as 
tumour necrosis factor alpha (TNF-a), cadherin, and Ras have been suggested 
to be associated with bladder cancer risk (Franekova, Halasova et al. 2008). 
 
1.1.2. Pathology, staging and grading of bladder cancer  
More than 90% of cancers arising in the bladder are of urothelial origin 
(or transitional cell carcinoma) (Lopez-Beltran 2008). Some urothelial cancers 
show a mixed pattern with squamous features or glandular component (Martin, 
Jenkins et al. 1989). Other less common pathologies are squamous cell 
carcinoma, adenocarcinoma or other rare variants such as small-cell 
carcinoma, comprising approximately 5%, 2% and less than 1% of bladder 
cancers respectively (Lopez-Beltran 2008). Most (80%) urothelial cancers of 
the bladder are non-muscle invasive at initial presentation (Wood 2012). 
Urothelial cancers can have different patterns of growth including the flat 





grade and the more solid sessile growths which can be muscle invasive (Wood 
2012).  
 
In 1998, the International Society of Urological Pathology (ISUP) 
recommended to move away from the traditional three categories of grading, 
namely grades 1, 2, and 3 (from low to high grade) and to adopt a new 
nomenclature to better reflect the recurrence and progression rates of 
urothelial cancers, which was eventually accepted by the World Health 
Organization (WHO) (Wood 2012).  Tumor grading is classified based on the 
architectural (comprising type of papillae if present and cellular organization) 
and cytologic (comprising nuclear size, shape, variation in nuclear chromatin, 
presence of prominent nucleoli, number of mitoses, and presence of umbrella 
cells) features (Wood 2012). The WHO 2004 classification of Urothelial 
tumours is shown in Table 1.1 (Montironi and Lopez-Beltran 2005).  
 
Table 1.1. 2004 WHO Classification of Urothelial Neoplasia (Montironi and 
Lopez-Beltran 2005). Table reproduced by permission of SAGE Publications. 
 
 
Noninvasive Urothelial Neoplasia 
Hyperplasia (flat and papillary) 
Reactive atypia 
Atypia of unknown significance 
Urothelial dysplasia (low-grade intraurothelial neoplasia) 
Urothelial carcinoma in situ (high-grade intraurothelial neoplasia) 
Urothelial papilloma 
Urothelial papilloma, inverted type 
Papillary urothelial neoplasm of low malignant potential 
Noninvasive low-grade papillary urothelial carcinoma 
Noninvasive high-grade papillary urothelial carcinoma 
 
Invasive Urothelial Neoplasia 
Lamina propria invasion 








The bladder has three main histologic layers, comprising the (1) 
urothelium, (2) lamina propria, which is a suburothelial loose connective 
tissue, and (3) detrusor muscle or muscularis propria. Tumour staging reflects 
the degree of invasion into the different layers of the bladder wall or adjacent 
organs by the tumour (Fig. 1.1). It is important in distinguishing the different 
therapeutic approaches that may be required to be performed. Currently, the 
most widely accepted staging system is the Tumour-Node-Metastases (TNM) 
System, formed by the American Joint Commission on Cancer in combination 
with the International Union Cancer Consortium. The updated TNM system in 




Fig. 1.1. Staging of bladder cancer. CIS (or Tis) is a flat, high-grade lesion 
confined to the urothelium, TA denotes a papillary tumour confined to the 
urothelium, T1 tumours invade the lamina propria, and tumors T2 – T4 
tumours invade the muscularis propria and beyond (Wood 2012). Tumors CIS, 
TA and T1 are considered non-muscle invasive (superficial) and T2 or greater 







Table 1.2. 2009 TNM Classification of Bladder Cancer 
Primary Tumor (T) 
 TX = Primary tumour cannot be assessed  
 T0 = No evidence of primary tumour  
 Tis = Carcinoma in situ: “flat tumour” 
 Ta =Noninvasive papillary carcinoma 
 T1 = Tumour invades subepithelial connective tissue 
 T2= Tumour invades muscularis propria 
                     T2a = Tumour invades superficial muscularis propria (inner half)  
                     T2b = Tumour invades muscularis propria (outer half)  
 T3 = Tumour invades perivesical tissue  
                     T3a = Microscopic invasion  
                     T3b = Macroscopic invasion (extravesical mass) 
 T4 = Tumour Tumour invades any of the following: prostatic stroma, seminal 
vesicles, uterus, vagina, pelvic wall, abdominal wall 
 
                     T4a = Tumour invades prostatic stroma, uterus, vagina  
                     T4b = Tumour invades pelvic or abdominal wall  
 
Regional Lymph Nodes (N)  
 NX = lymph nodes cannot be assessed  
 N0 = No lymph node metastasis  
 N1 = Single regional lymph node metastasis in the true pelvis (hypogastric, 
obturator, external iliac, or presacral lymph node) 
 
 N2 = Multiple regional lymph node metastasis in the true pelvis (hypogastric, 
obturator, external iliac, or presacral lymph node metastasis) 
 
 N3 = Lymph node metastasis to the common iliac lymph nodes 
 
Distant Metastasis (M)  
 MX = Presence of distant metastasis cannot be assessed  
 M0 = No distant metastasis  







1.1.3. Tumour biology and natural history of bladder cancer 
 Urothelial cancers have a tendency to recur and may sometimes 
progress. Low grade Ta lesions recur in 50 to 70% and progress in 
approximately 5% of cases, while patients with high grade T1 tumours may 
experience more than 80% recurrence rate and progression in approximately 
50% of the time (Jones 2012). This behavior tends to be more dependent on 
grade than stage for non-muscle invasive bladder cancer (Jones 2012). CIS is a 
flat, non-invasive high grade urothelial carcinoma, and not ‘pre-malignant’ 
(Jones 2012). It can be regarded as a precursor for the development of invasive 
cancer. Muscle invasive urothelial cancers are by definition high grade, and 
potentially lethal due to their propensity to progress and cause metastases 
(Wood 2012). 
 
1.1.4. Molecular biology of bladder cancer 
The interesting feature of urothelial carcinoma is that there exist two 
distinct groups of tumours which show divergent clinical behaviour  (Knowles 
2006). Non-invasive papillary tumours constitute more than 70 to 80% of 
diagnosed bladder lesions. They often recur but infrequently progress to 
muscle invasion (10 – 20%). On the other hand, about 20 to 30% of diagnosed 
bladder tumours are muscle-invasive. These have a poor prognosis with 
overall less than 50% survival at 5 years (Knowles 2006). These two groups of 







Based on current evidence, it has been proposed that there are three 
possible molecular routes to developing urothelial cancer (Fig. 1.2.) (Knowles 
2008). The first pathway is from normal urothelium to hyperplasia or minimal 
dysplasia, to low grade non-invasive papillary tumours, characterized by 
chromosome 9 deletions, and activating mutations of fibroblast growth factor 
receptor-3 (FGFR3) and phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA). These tumours are genetically stable 
although they recur often. The second pathway is from normal urothelium to 
CIS, and subsequently to T1 and muscle-invasive cancer, characterized by less 
common chromosome 9 deletions (9q) and infrequent FGFR3 mutations, but 
has high rate of early p53 mutations. These tumours are genetically unstable 
and they accumulate many genetic events including Rb1 changes, 8p deletions 
etc. A third hypothetical pathway (where firm evidence is lacking) is from 
normal urothelium to hyperplasia or dysplasia, to high grade non-invasive 
papillary carcinoma and possibly to develop into T1 tumours and form 












Genomic alterations in bladder cancer are mainly in the form of 
somatic mutations rather than germline mutations, unless they are associated 
with a specific cancer due to systemic disease or syndromes (Jones 2012). The 
genetic alterations in bladder cancer described to-date fall into two main 
categories: (1) alterations that are common to all bladder cancers such as 
deletions of chromosome 9 and RAS gene mutations, which have been found 
at similar frequency in tumours of all grades and stages, (2) alterations that 
have relevance to tumour stage/grade classification, where the hallmark 
genetic alterations of low grade Ta tumours are the FGFR3 mutations, while 
the muscle invasive cancers have high rates of mutations in p53 and pRb 
(Knowles 2008; Jones 2012). 
 
Genetic changes of Ta and muscle invasive bladder cancers are found in 
Table 1.3 (Knowles 2008). T1 bladder carcinomas are a group that is still 
difficult to define, both in terms of their natural history and molecular profile 
(Knowles 2008). Some T1 tumours are simply those that are destined to be 
muscle invasive but were sampled while along that journey. This is shown by 
some T1 tumours having molecular alterations similar to those of muscle 
invasive disease (Richter, Wagner et al. 1999). On the other hand, in studies of 
multifocal tumours in a single patient, T1 cancers when amongst majority of 
Ta lesions, are shown to have genetic alterations similar with the Ta tumours 
(van Tilborg, de Vries et al. 2000; Zieger, Dyrskjot et al. 2005). Hernandez et 
al performed a recent study of the FGFR3 and TP53 mutation status of 119 
patients with T1G3 bladder cancer, and suggested that their molecular features 





molecular pathways proposed for bladder cancer development and progression 





















































Table 1.3. Genetic changes identified in Ta and invasive (≥T2) bladder 
tumours (Knowles 2008). 
 
Gene (cytogenetic location) Alterations  




Activating mutations Activating mutations 
FGFR3 (4p16) Activating mutations Activating mutations 
ERBB2 (17q) - Amplification/overexpression 
CCND1(11q13) Amplification/overexpression Amplification/overexpression 
PIK3CA (3q26) Activating mutations - 
MDM2 (12q13) Overexpression Amplification/overexpression 
E2F3 (6p22) - Amplification/overexpression 
Tumour suppressor genes 




PTCH (9q22)  Deletion/mutation  Deletion/mutation  
DBC1 (9q32-33)  Deletion/methylation  Deletion/methylation  
TSC1 (9q34)  Deletion/mutation  Deletion/mutation  
PTEN (10q23) - Homozygous 
deletion/mutation 
RB1 (13q14) - Deletion 
TP53 (17p13) - Deletion/mutation 
DNA copy number changes; Target gene(s) unknown* 
2q Deletion Deletion 
5q - Deletion 
6q - Deletion 
8p Deletion Deletion 
9p Deletion Deletion 
9q Deletion Deletion 
10p Deletion - 
10q Deletion Deletion 
11p Deletion/LOH Deletion 
11q - Deletion 
13q Deletion Deletion 
15q - Deletion 
16q - Deletion 
17q Deletion Deletion 
18q Deletion Deletion 
Y Deletion Deletion 
1q Gain Gain 
3q - Gain 
5p - Gain 
7p - Gain 
8q - Gain 
10p - Gain 
17q Gain Gain 
20p - Gain 
20q Gain Gain 
1q22 - Amplification 
3p24 - Amplification 
6p22 - Amplification 





8p21-22 and q24 - Amplification 
10p13-14 - Amplification 
11q13 (including CCND1) Amplification - 
12q15 - Amplification 
17p21 - Amplification 
20q13 - Amplification 





1.2. Current management of non-muscle invasive bladder cancer 
(NMIBC) 
Urothelial carcinomas (UC) which are limited to the mucosa (Ta) and 
lamina propria (T1) are usually termed as NMIBC. Approximately 75% of 
UCs are non-muscle invasive at the time of diagnosis. The overall prognosis is 
generally good and not life threatening. However, the management is 
challenging due to its tendency to recur and possibility of progression to the 
more potentially dangerous muscle-invasive disease and metastatic bladder 
cancer. Owing to the propensity to recur, bladder cancer is the most expensive 
disease to treat, with an estimated cost  of US$96,000 to US$187,000 per 
patient in the United States from diagnosis to death (2001 values), due to the 
long-term survival associated with non-muscle-invasive disease combined 
with life-long surveillance (Botteman, Pashos et al. 2003). The major 
challenge in the management of bladder cancer is the prevention of recurrence 
and progression of disease. NMIBC is currently managed with a local 
resection and often the usage of adjuvant intravesical chemotherapy or 
immunotherapy, depending on the risk of recurrence or progression based on 







Transurethral resection of bladder tumour (TURBT) is the current 
standard primary local therapy for NMIBC. It allows for histological diagnosis 
of resected tumours and is also a staging tool to determine the presence of 
muscle invasion. Hence, it is important for tumours to be resected deep 
enough to obtain detrussor muscle in the specimen for histological evaluation, 
to achieve accurate staging. Although it usually provides excellent local 
control of the disease when all visible tumours are resected, it may not protect 
against recurrence of tumour, as nearly 50 – 70% of NMIBC tend to recur after 
resection, and 10 – 20% progress to muscle invasive disease (Kaufman, 
Shipley et al. 2009). Repeat TURBT soon after the first is recommended 
especially for high grade and/or T1 lesions, or when no muscle was detected in 
the initial TURBT, due to the frequent possibility of unresected residual 
tumour or clinical understaging. Once no muscle invasion is confirmed, 
TURBT is frequently followed by adjuvant intravesical therapy when 
indicated. 
 
1.2.2. Intravesical therapy 
Adjuvant intravesical chemotherapy or immunotherapy is used to 
prevent recurrence and progression of NMIBC. The aim of using the 
intravesical route is to maximize exposure of the tumour to cytotoxic agents 
and also to limit toxicity as compared to a systemic administration. 
 
1.2.2.1. Intravesical chemotherapy 
Intravesical chemotherapy has been used as prophylaxis in the peri-





prevent tumour implantation which may be responsible for many early 
recurrences. Mitomycin C (MMC) has been the most widely used agent for 
this purpose. A meta-analysis by the European Organization for Research and 
Treatment of Cancer (EORTC) observed that low risk patients had about 39% 
decrease in the odds for recurrence, and the number needed to treat to prevent 
one recurrence was 8.5 (Sylvester, Oosterlinck et al. 2004). This meta-analysis 
also showed that chemotherapeutic drugs such as MMC, epirubicin and 
pirarubicin all could significantly decrease recurrence in patients with single 
or multiple tumours. However, a prospective randomised multicentre trial 
suggested that the benefit appears to be limited to low risk patients 
(Gudjonsson, Adell et al. 2009). Intravesical chemotherapy has also been used 
as adjuvant therapy, although its role is less clear compared to intravesical 
BCG. A meta-analysis suggested that a 3-year recurrence was decreased by as 
much as 70% following intravesical chemotherapy when compared with 
TURBT alone (Huncharek, McGarry et al. 2001). Although intravesical 
chemotherapy has been shown to reduce the recurrence rate in the short term 
by an average of 14%, there is no evidence that it reduces the long-term 
incidence of recurrence or the risk of progression to muscle invasive disease 
(Lamm, Riggs et al. 1995). Also, another meta-analysis did show that tumour 
progression rate was higher than that seen with intravesical BCG with 
maintenance therapy (Bohle and Bock 2004).  Improved or device-assisted 
agent delivery such as electromotive drug adiminstration (EMDA) is shown to 
significantly enhance the effectiveness of intravesical chemotherapy agents. 
However, its independent use has not been shown to be superior to intravesical 





Gemcitabine, which has shown promise in phase 2 trials, valrubicin, 
apaziquone and docetaxel (Chiong and Esuvaranathan 2010; Nargund, 
Tanabalan et al. 2012).  
 
1.2.2.2. Intravesical Bacillus Calmette-Guerin (BCG) 
 
1.2.2.2.1.  Efficacy of BCG 
 
Since its introduction for the treatment for bladder cancer in 1976 by 
Morales et al, intravesical BCG has been shown to be the most effective 
intravesical agent to-date for NMIBC and is currently standard therapy for 
adjuvant treatment in high-risk patients, particularly CIS (Morales, Eidinger et 
al. 1976; Sylvester, van der et al. 2002). The precise mechanism of action for 
this immunotherapy is still not known despite intensive study. However, it is 
currently known that the initial crucial step is the binding of BCG to 
fibronectin on the urothelium of the bladder wall (Zhao, Schorey et al. 2000). 
This leads to a massive local inflammatory response which involves the 
increased production of numerous cytokines associated with a predominantly 
T-helper type-1 (Th1) response (Jones 2012). This activates the cell-mediated 
immunity which is believed to be cytotoxic to tumours cells (Jones 2012). 
 
The use of intravesical BCG after TURBT was shown to have an odds 
ratio for recurrence of 0.39 compared to TURBT alone (van der Meijden, 
Sylvester et al. 2005). It has also been shown to be superior to intravesical 
chemotherapy in terms of reducing recurrence and beneficial in the prevention 
of progression to muscle invasive cancer, and can also positively influence the 





Blumenstein et al. 1995; Malmstrom, Wijkstrom et al. 1999). In a meta-
analysis of more than 2700 patients with NMIBC, patients who received 
intravesical BCG had a tumor recurrence rate of 38.6% compared to 46.4% in 
the intravesical MMC group, at a median follow-up time of 26 months (Bohle, 
Jocham et al. 2003). There was an overall statistically significant superiority of 
BCG versus MMC efficacy in reducing tumour recurrence especially when 
BCG maintenance was performed, at an odds ratio of 0.56. In another meta-
analysis of 9 trials that included 2820 patients with NMIBC, intravesical BCG 
with maintenance had a 32% reduction in recurrence risk ( p < 0.0001) 
compared to MMC, while there was a 28% risk increase ( p = 0.006) for BCG 
in the trials without BCG maintenance (Malmstrom, Sylvester et al. 2009). It 
was concluded that BCG with maintenance was more effective than MMC in 
patients regardless of whether they had previously received intravesical 
chemotherapy or not. In a long term randomized Phase 3 study by the EORTC 
of 837 patients with intermediate or high risk NMIBC and followed up at a 
median of 9.2 years, BCG maintenance had a significantly longer time to first 
recurrence (p < 0.001) compared to intravesical epirubicin with maintenance 
(Sylvester, Brausi et al. 2010). Although there was no difference for disease 
progression seen, time to distant metastases (p = 0.046), overall survival (p = 
0.023), and disease-specific survival (p = 0.026) were significantly longer with 
BCG therapy as compared with epirubicin treatment (Sylvester, Brausi et al. 
2010). Intravesical BCG maintenance has also been shown to reduce the risk 
of progression in NMIBC in two meta-analyses, which showed reduction of 
27% (9.8% for BCG vs 13.8%  for non-BCG, with median follow-up of 2.5 





26 months) in progression to a higher tumour stage or the development of 
metastatic disease, respectively (Sylvester, van der et al. 2002; Bohle and 
Bock 2004).  
 
Intravesical BCG remains the treatment of choice for CIS. In a long-
term prospective study by the Southwest Oncology Group (SWOG) comparing 
doxorubicin with BCG, 45% of the BCG-treated patients with CIS were 
disease-free at 5 years, compared with 18% when treated with doxorubicin 
(Lamm, Blumenstein et al. 1991). In another prospective randomized study by 
SWOG that compared BCG maintenance to no maintenance for NMIBC 
patients, patient with CIS who received additional maintenance BCG cycles 
benefitted as shown by a significantly improved overall response rate from 
68.1% to 83.8% (p = 0.004) (Lamm, Blumenstein et al. 2000). Finally, a meta-
analysis was performed of nine trials involving 700 patients with CIS, 
comparing BCG to chemotherapy which included either MMC, epirubicin, 
adriamycin, or sequential MMC / adriamycin (Sylvester, van der Meijden et 
al. 2005). It reported that BCG treated patients had 68.1% complete response 
compared to 51.5% in patients on chemotherapy (OR 0.53, p = 0.0002). At a 
median follow-up of 3.6 years,  the disease free rate for BCG treated and 
chemotherapy treated  patients were 46.7% and 26.2%  respectively (OR 0.41, 
p ˂0.0001) (Sylvester, van der Meijden et al. 2005). However, Herr et al 
showed in a review of 1021 patients with high-risk NMIBC who were not 
given BCG maintenance but selectively retreated with a 6-week course of 
BCG for noninvasive tumor relapse, that their 5-year clinical outcome 





maintenance BCG (Herr, Dalbagni et al. 2011). They suggested that this 
strategy may be investigated as an alternative to BCG maintenance therapy. 
Thus far, the average response to a second BCG induction course is 
approximately 25% overall and about 30% for patients with CIS (Sylvester, 
van der et al. 2002; Bohle and Bock 2004; Jones 2012). 
 
Generally, intravesical BCG is recommended for patients with NMIBC 
that are at intermediate to high risk for recurrence or progression, with 
intravesical chemotherapy maintenance as an option (Hall, Chang et al. 2007; 
Babjuk, Oosterlinck et al. 2008). The optimal treatment schedule of BCG is 
yet to be determined. Typically patients are given an induction treatment 
comprising six weekly instillations, about 2 to 4 weeks after their TURBT. 
Most guidelines recommend continuation with maintenance therapy for 
variable duration of up to 1 - 3 years (Hall, Chang et al. 2007; Babjuk, 
Oosterlinck et al. 2008). However, it was noted in the SWOG trial that first 
described a 3-year maintenance therapy that only 16% of patients were able to 
tolerate the full dose-schedule regimen, due to toxicities (Lamm, Blumenstein 
et al. 2000).  
 
1.2.2.2.2. Toxicity of BCG 
BCG toxicity is usually a consequence of immune stimulation, and can 
be local or systemic. Local side effects are usually more common and less 
severe than systemic side effects. They could include lower urinary tract 
symptoms (such as dysuria, frequency and urgency), haematuria, cystitis and 





arthralgias, skin reactions, anaphylaxis and sepsis (which could have other 
organ manifestation such as pneumonitis, hepatitis and epididymo-orchitis). 
Most patients experience adverse effects to some extent which are usually 
local effects and transient. Severe side effects occur in <5% of all patients 
undergoing BCG treatment (Babjuk, Oosterlinck et al. 2008). Dose adjustment 
is one of the most common methods to reduce the side effects of BCG. Some 
studies have shown an up-regulation of the Th1 response with a lower dose of 
BCG (Jones 2012). A one-third dose of BCG has been shown in a randomized 
trial to produce similar efficacy in preventing recurrence and progression 
compared to full dose BCG, but with significantly less toxicity. It is also noted 
that there may be some concern about its routine use in high risk tumours 
(Martinez-Pineiro, Flores et al. 2002; Martinez-Pineiro, Martinez-Pineiro et al. 
2005). 
 
1.2.2.2.3. BCG failure 
Overall, approximately 20% of patients on maintenance therapy suffer 
from BCG intolerance thereby limiting its use, about 30-50% of patients 
develop recurring tumours within 5 years, and nearly 90% recur by 15 years, 
and there are also some who are BCG resistant or BCG refractory (Lamm, 
Blumenstein et al. 1991; Lamm and Griffith 1992; Nadler, Catalona et al. 
1994; van der Meijden, Sylvester et al. 2003; Witjes 2006; Yates, Brausi et al. 
2012). Overall failure rate for BCG is 30 to 50%, with the significant risk of 
progression to muscle invasion especially for high risk NMIBC, and patients 
who progress to muscle-invasive disease after BCG have a poorer prognosis 





Hollander et al. 2004; van den Bosch and Alfred Witjes 2011; Yates, Brausi et 
al. 2012).  Once muscle invasion occurs, two thirds of patients die within 5 
years (Ries LAG 2002). Therefore most guidelines recommend that radical 
cystectomy should be offered to patients who are failing BCG (Babjuk, 
Oosterlinck et al. 2008; Yates, Brausi et al. 2012). These limitations have 
driven efforts in search of other new therapies.  
 
Intravesical BCG has been combined with interferon therapy, as one 
strategy to improve BCG efficacy but data is limited. Several initial series 
suggested a potential superiority or the possibility of reducing BCG dosage to 
decrease toxicity with such a combination (Jones 2012).  Initial series using 
this combination with BCG naïve patients showed promise although an 
unpublished but presented result of a randomized trial in 2008, comparing 
BCG with or without interferon for BCG naïve NMIBC patients did not show 
a difference in outcome (Nepple, Aubert et al. 2009). However, our group had 
also previously presented unpublished results of a randomized phase 3 study in 
BCG naïve but largely BCG pre-immune population showing a significant 
difference in favour of the one-third dose BCG plus interferon therapy at a 
median follow-up of 60 months (Nepple, Aubert et al. 2009; Chiong and 
Esuvaranathan 2010). O’Donnell et al reported 63% and 53% disease-free 
rates at 12 and 24 months respectively, using the combination of intravesical 
BCG and interferon for NMIBC patients (O'Donnell, Krohn et al. 2001). 
Several series using intravesical BCG plus interferon therapy for BCG failures 
suggested that some may be salvaged, with recurrence-free survival between 





randomized phase 2 trial of more than 1000 patients treated with intravesial 
BCG plus interferon, 59% and 45% of patients naïve to BCG and those who 
had BCG failure, respectively, remained disease free at 24-month median 
follow-up (Joudi, Smith et al. 2006). This strategy of combining BCG with 
interferon remains an option in select patients who fail intravesical BCG 
(Nepple, Aubert et al. 2009). Other bladder-preserving options for BCG 
failures are still being investigated, which include intravesical chemotherapy 
(such as gemcitabine, and docetaxel), device-assisted intravesical 
chemotherapy, and sequential combinations of intravesical BCG and 
chemotherapy (Yates, Brausi et al. 2012). 
 
1.3. Predictive factors for clinical outcome in bladder cancer 
As previously mentioned, the two main features of NMIBC are the 
tendency to recur and progress. Factors that predict for tumour behaviour in 
patients with NMIBC have been previously investigated. The risks are mainly 
related to pathological characteristics (such as stage, grade, tumour 
morphology, lymphovascular invasion (LVI)), tumour multiplicity and size, 
and presence or absence of CIS (Nargund, Tanabalan et al. 2012). Many of the 
risk factors were concluded from series where intravesical therapy was given 
after TURBT (Nargund, Tanabalan et al. 2012). Sylvester et al performed a 
combined analysis of 2596 NMIBC patients included in seven randomized 
phase III studies performed by the EORTC, that compared prophylactic 
treatments after TURBT in stage Ta, T1, and Tis bladder cancer patients 
(Sylvester, van der Meijden et al. 2006). Seventy-eight percent of patients 





chemotherapeutic agents (Sylvester, van der Meijden et al. 2006).  
Multivariate analysis for factors that influenced time to recurrence and 
progression showed significance in the following features: number of tumours, 
tumour size, prior recurrence rate, T stage, CIS, and grade. A simple scoring 
system was then derived based on these clinical and pathological factors, to 
help predict probabilities of recurrence and progression at one and five years 
(Sylvester, van der Meijden et al. 2006). This is currently one of the more 
common risk scoring systems being used for NMIBC. 
 
1.3.1. Predictors of BCG failure 
There are at present no variables that are capable to accurately predict 
response to BCG therapy on an individual basis. The risk factors that are 
commonly associated with BCG failure include female gender, older age, 
tumour stage (depth of invasion), grade, presence of CIS, multifocality, 
tumour size, LVI, high risk histologic variants, tumour recurrence, detectable 
disease at 3-month cystoscopy, 2 or more courses of BCG, and timing of 
failures (early vs late) (Yates, Brausi et al. 2012). 
 
1.3.1.1. Clinical and pathological risk factors for BCG failure 
Patient age has been suggested to be associated with BCG response 
and may be an independent factor predictive of progression (Takashi, Wakai et 
al. 2002; Saint, Salomon et al. 2003; Fernandez-Gomez, Solsona et al. 2008). 
This may be due to decreasing ability to mount an adequate immune response 
with increasing age, as the efficacy of BCG therapy depends on the innate 





time to recurrence following BCG therapy for NMIBC patients, in a 
multivariate analysis of four Spanish Club Urológico Español de Tratamiento 
Oncológico (CUETO) randomized trials (Fernandez-Gomez, Solsona et al. 
2008). Recently, Palou et al also reported that female gender was prognostic 
for recurrence, progression and disease-specific survival in a retrospective 
review of 146 T1G3 NMIBC patients treated with BCG (Palou, Sylvester et al. 
2012).   
 
Previous large-scale, prospective studies have demonstrated that the 
TNM stage of NMIBC can predict tumour progression. The risk of 
progression is more than twice greater for stage T1 compared to Ta, and has a 
hazard ratio between 2.7 and 5.8 for grade 3 (high grade) compared to lower 
grades of disease (Herr, Badalament et al. 1989; Martinez-Pineiro, Flores et al. 
2002; Sylvester, van der Meijden et al. 2006; Fernandez-Gomez, Solsona et al. 
2008). CIS often co-exist with high grade papillary tumours. The EORTC 
meta-analysis had shown that progression rates were worse for T1G3 tumours 
with concomitant CIS compared to those without CIS (74 vs 29% at 5 years, 
respectively) (Sylvester, van der Meijden et al. 2006), suggesting that CIS is 
an independent prognostic factor for NMIBC. Takashi et al reported that 
concomitant CIS was significantly associated with progression in a cohort of 
NMIBC patients treated with intravesical BCG (Takashi, Wakai et al. 2002). 
However, the multivariate analysis of four CUETO randomized trials and 
Kakishvili et al. found that CIS independently predicted for recurrence but not 
progression (Fernandez-Gomez, Solsona et al. 2008; Kakiashvili, van Rhijn et 





BCG, CIS involving the prostatic urethra was found in 10.3% of cases, which 
also strongly predicted for recurrence and progression (Palou, Sylvester et al. 
2012). CIS involving the prostatic urethra was also previously reported to be a 
bad prognostic factor in NMIBC (Solsona, Iborra et al. 1995; Palou, Xavier et 
al. 1996). 
 
Although tumour size more than 3 cm and multifocality are suggested 
to predict for recurrence and progression in NMIBC, their predictive value for 
BCG response is controversial (Saint, Salomon et al. 2003; Sylvester, van der 
Meijden et al. 2006). However, several groups have reported that multifocality 
predict significantly for recurrence in BCG treated patients, with a hazard ratio 
of about 1.5 (Martinez-Pineiro, Flores et al. 2002; Sylvester, van der Meijden 
et al. 2006; Fernandez-Gomez, Solsona et al. 2008). There is however limited 
data on its implication on progression. Hurle et al reported in a small study 
that tumour size was an independent prognostic factor in T1G3 NMIBC 
patients treated with BCG (Hurle, Losa et al. 1999). Multifocality was found 
to be an independent predictor for recurrence but not for progression, after 
BCG treatment in a multivariate analysis of four CUETO randomized trials 
(Fernandez-Gomez, Solsona et al. 2008).  
 
Histologic variants such as squamous cell carcinoma and 
adenocarcinoma of the bladder are behaviourally different and are not suitable 
for BCG treatment. It was reported in a single centre series that the 
progression rate for micropapillary variant of urothelial cancer treated with 





al. 2007). The authors concluded that intravesical therapy was ineffective for 
micropapillary bladder cancer and early radical cystectomy should be offered. 
LVI seen in the histology specimen has been deemed as independent factor for 
progression and metastases especially in T1 NMIBC, and decreased survival 
in radical cystectomy patients (Quek, Stein et al. 2005; Cho, Seo et al. 2009). 
However, its utility in clinical decision making for BCG is still controversial. 
 
The pattern of recurrence has strong prognostic significance for BCG 
therapy. It is known that early recurrence carries a worse prognosis than 
delayed recurrence. Multiply-recurrent tumours carry a hazard ratio of 2.3 for 
continued recurrence and 2.0 for progression to muscle-invasive disease 
(Martinez-Pineiro, Flores et al. 2002). The multivariate analysis of four 
CUETO randomized trials also showed that BCG was less effective in 
recurrent tumours (Fernandez-Gomez, Solsona et al. 2008). Tumour 
recurrence seen at the first post-BCG treatment cystoscopy have a 60 to 80% 
chance of developing progression eventually, and is one of the worst 
prognostic indictors (Herr, Badalament et al. 1989; Luo, Chen et al. 1999; 
Solsona, Iborra et al. 2000; Lockyer, Sedgwick et al. 2002). 
 
1.3.1.2. Molecular risk factors for BCG failure 
Although clinical and pathological factors have been extensively 
studied, there are currently relatively few molecular markers analysed for their 
predictive role in patients treated with BCG. There are currently no reliable 
molecular markers that can be incorporated with the previously discussed 





therapy. Some molecular markers (cathepsin E, maspin, polo-like kinase 1, 
survivin, Galectin-3, Cyclin D1, MCM7, TRIM29, UBE2C, Profilin 1 etc.) are 
suggested to have prognostic value in NMIBC but were not studied specific to 
BCG therapy (Canesin, Gonzalez-Peramato et al. 2010; Fristrup, Ulhoi et al. 
2012; Zoidakis, Makridakis et al. 2012; Fristrup, Birkenkamp-Demtroder et al. 
2013). Saint et al evaluated 102 patients with NMIBC treated with BCG, and 
showed that pretreatment p53 nuclear overexpression was associated with a 
high risk of disease recurrence, progression and cancer death after BCG 
therapy (Saint, Le Frere Belda et al. 2004). Lopez-Beltran et al and Palou et al 
also demonstrated that p53 predicted for progression in BCG treated patients 
(Lopez-Beltran, Luque et al. 2004; Palou, Algaba et al. 2009). However, others 
have shown that p53 was not associated with post BCG outcome (Lebret, 
Becette et al. 1998; Zlotta, Noel et al. 1999; Peyromaure, Weibing et al. 2002; 
Esuvaranathan, Chiong et al. 2007; Oderda, Ricceri et al. 2013). Recently, 
Oderda et al performed a prospective evaluation of molecular markers in 192 
NMIBC patients treated with BCG maintenance (Oderda, Ricceri et al. 2013). 
They found that Ki-67 was significantly associated with overall survival and 
concluded that p53 was not useful to predict BCG response (Oderda, Ricceri et 
al. 2013). Previously, Ki-67 has also been found to be predictive of recurrence 
and progression after BCG therapy (Lebret, Becette et al. 1998; Zlotta, Noel et 
al. 1999; Lopez-Beltran, Luque et al. 2004). 
 
Rb is another tumour suppressor involved in cell cycle that has been 
studied with regards to BCG response. Our group had shown that while pRb 





treated with BCG plus interferon (Esuvaranathan, Chiong et al. 2007).  
Cormio et al further showed that pRb would also predict for progression and 
disease-free survival after BCG therapy (Cormio, Tolve et al. 2009). Recently,  
Agundez et al reported in a retrospective series of 91 T1G3 NMIBC patients 
treated with BCG without maintenance, that methylation status of 25 tumour 
suppressor genes were able to help distinguish patients who would or would 
not respond to BCG therapy (Agundez, Grau et al. 2011). Others have also 
reported the usefulness of methylation status (Polyamine-modulated factor-1 
and Myopodin methylation) in predicting BCG response in T1-high grade 
NMIBC patients (Alvarez-Mugica, Cebrian et al. 2010; Alvarez-Mugica, 
Fernandez-Gomez et al. 2013). Ezrin was also recently suggested to predict for 
recurrence and progression after BCG therapy but further data is limited 
(Palou, Algaba et al. 2009). All these markers will require further prospective 
study to validate their usefulness in predicting BCG response. 
 
1.3.1.3. Inflammatory markers for BCG response 
As the anti-cancer activity of BCG is thought to be due to the 
inflammatory response, several molecules and inflammatory cells have been 
studied as potential markers of BCG response. Interleukin-2 (IL-2) is a Th1 
cytokine and several studies have found that high urinary levels of IL-2 after 
BCG correlated to increased recurrence-free survival (de Reijke, de Boer et al. 
1996; Saint, Patard et al. 2002; Watanabe, Matsuyama et al. 2003). Similarly, 
high urinary levels of IL-8 and IL-18, either before each BCG or after BCG 
instillations were associated with increased recurrence-free survival in several 





Kumar, Dubey et al. 2002; Sagnak, Ersoy et al. 2009). In contrast, Rabinowitz 
et al could not show the association between urinary IL-8 measured before the 
first and 6th BCG instillations, and BCG outcome (Rabinowitz, Smith et al. 
1997). Other inflammatory markers studied that may also show prognostic 
value include TRAIL, tumour-infiltrating macrophages and urinary dendritic 
cells (Zuiverloon, Nieuweboer et al. 2012). Further validation studies are 
needed before these markers can be applied to the clinic. 
 
1.3.1.4. Genetic risk factors for BCG failure 
1.3.1.4.1. Gene polymorphisms in NMIBC  
 
The current knowledge on genetic determinants in the risks of 
developing bladder cancer, recurrence and progression, and response to 
therapy is limited.  Two groups who performed genome–wide association 
studies  had recently identified several bladder cancer susceptibility loci (SNP 
markers) in the gene regions MYC, TP63, TERT, CLPTM1L, PSCA and 
TACC3/FGFR3 (Grotenhuis, Vermeulen et al. 2010). A number of candidate 
gene studies have investigated the association of germline genetic 
polymorphisms and the risk of recurrence and progression in NMIBC patients. 
The candidate genes include cytokine genes (e.g. IL-6), DNA repair genes 
(e.g. hOGG1, ERCC6, XRCC1, ERCC4), cell cycle control pathway genes 
(eg. p53, CDKN2A, CCND1, HRAS), xenobiotic metabolism pathway genes 
(eg. GSTM1, hGPX1, NQO1, CDH1), angiogenesis pathway genes (eg. 
HIF1A) and G-protein signaling pathway genes (eg. GNB4) (Grotenhuis, 







1.3.1.4.2. DNA Repair gene polymorphisms and response to BCG  
One of the major pathways for DNA repair is nucleotide excision 
repair (NER). More efficient DNA repair capacity have been seen in variant 
alleles of NER genes compared with the wild-type alleles, and may portend a 
less favourable treatment outcome (Gu, Zhao et al. 2005; Mittal, Singh et al. 
2008; Gangawar, Ahirwar et al. 2010; Gangwar, Mandhani et al. 2010; 
Zuiverloon, Nieuweboer et al. 2012). A few studies in different ethnicities 
have shown decreased recurrence-free survival or higher recurrence risks in 
patients with XPA, ERCC6, XRCC1, XPC, ERCC2 gene polymorphisms, in 
BCG treated patients (Gu, Zhao et al. 2005; Mittal, Singh et al. 2008; 
Gangawar, Ahirwar et al. 2010; Gangwar, Mandhani et al. 2010; Zuiverloon, 
Nieuweboer et al. 2012). Very few of these studies have been validated in 
independent patient cohorts of different ethnicity.  
 
1.3.1.4.3. Cytokine gene polymorphisms and response to BCG 
As BCG incites an immune and inflammatory response, resulting in 
destruction of bladder cancer cells, polymorphisms in cytokine genes may 
contribute to different responses to BCG therapy. The majority of the studies 
were performed by the same group in North Indian patients suggesting the 
utility of IL-6, IL-8, TNF-α, IFN-γ, TGF-β and NF-κB gene polymorphisms in 
predicting recurrence after BCG therapy (Ahirwar, Kesarwani et al. 2008; 
Ahirwar, Agrahari et al. 2009; Ahirwar, Mandhani et al. 2009; Ahirwar, 
Mandhani et al. 2010). Others have also found IL-4 and IL-10 gene 





patients (Leibovici, Grossman et al. 2005; Basturk, Yavascaoglu et al. 2006; 
Srivastava, Gangwar et al. 2010). It was suggested that ethnic differences in 
cytokine gene variants may correlate with difference in bladder cancer risks 
and may also have differences in clinical outcome of bladder cancer (Ahirwar, 
Manchanda et al. 2011). 
 
1.3.1.4.4. Cell cycle and other gene polymorphisms and response to BCG 
Polymorphisms of Matrix Metalloproteinase genes (eg. MMP-1) and 
cell cycle control genes (eg. CASP9 and MDM2) have also been shown to 
correlate with susceptibility and response to BCG therapy in NMIBC patients 
(Gangwar, Mandhani et al. 2009; Gangwar and Mittal 2010; Srivastava, 
Gangwar et al. 2010). 
 
1.3.1.4.5. Oxidative stress gene polymorphisms and response to BCG 
Oxidative stress can cause protein, lipid, and DNA damage and has 
been implicated in cancer development. A number of oxidative stress genes, 
such as eNOS, MnSOD and GPX have been studied for association with 
cancer risks and clinical outcomes (Wei, Kamat et al. 2012). Human 
glutathione peroxidase (hGPX1) is a selenium-dependent enzyme that 
participates in detoxification of hydrogen peroxide, organic peroxides and 
cigarette smoke-derived oxidative radicals. The polymorphism at position 198 
has been associated with the risk of developing bladder cancer (Ichimura, 
Habuchi et al. 2004) and having a recurrence, in a prospective study of 
NMIBC patients receiving intravesical BCG (Zhao, Liang et al. 2005). More 





38 genes in the oxidative stress pathway, in 421 NMIBC patients, and found 
28 SNPs were associated with recurrence in the BCG-treated group. These 
suggest that genetic variations in the oxidative stress genes in NMIBC patients 
may affect response to therapy with BCG. 
 
1.3.1.4.6. Natural-resistance–associated macrophage protein 1 (NRAMP1) 
polymorphisms and response to BCG  
Skamene et al. had previously shown in the murine model that the Bcg 
(Nramp1) gene controls the host macrophages’ susceptibility to intracellular 
mycobacterial growth and their ability to respond to BCG infection (Gros, 
Skamene et al. 1981; Buu, Sanchez et al. 2000). This Bcg gene is located on 
chromosome 1, which is expressed in two allelic forms: Bcgs (susceptible), 
carried in BALB/c mice and Bcgr (resistant), carried by the BALB/c.CD2 
congenic CD-2 mice (Potter, O'Brien et al. 1983). Genetic variation in this Bcg 
gene resulted in phenotypically different inflammatory responses mediated by 
macrophages (Skamene, Gros et al. 1982). In an orthotopic murine bladder 
tumour model, Kadhim et al showed that intravesical BCG treatment caused 
significant tumor regression in the Bcgs strain of mice compared to controls 
and that no effect was seen on tumors of the Bcgr strain of mice suggesting a 
genetic control of the response of bladder cancer to BCG immunotherapy 
(Kadhim, Chin et al. 1997). The human NRAMP1 gene, an ortholog of the 
Bcg gene, located on chromosome 2, is about 88% homologous to the murine 
Bcg gene (Buu, Sanchez et al. 2000). NRAMP1 gene polymorphisms have 
also been shown to influence the variable susceptibility of different human 





Fujishima et al. 2000; Ryu, Park et al. 2000; Ma, Dou et al. 2002; Leung, Yip 
et al. 2007). There are up to 9 identified polymorphisms in the human 
NRAMP1 gene and 2 others in the 5’ and 3’ untranslated regions (UTR) (Buu, 
Sanchez et al. 2000). Fig 1.3. below details the sites of the NRAMP1 




Fig.1.3. Location of polymorphisms and sequence variants in the human 
NRAMP1 gene. Exons are indicated by the black vertical bars, numbered 1–
15, and the corresponding scale for the gene is indicated in kb (top horizontal 
line). The white vertical bar is an alternatively spliced exon (Buu, Sanchez et 
al. 2000).  Figure reproduced by permission of Oxford University Press. 
 
 
Decobert et al first analysed 5 NRAMP1 polymorphisms and suggested 
that only the D543N and (GT)n polymorphisms of the NRAMP1 gene were 
associated with recurrence-free survival in a cohort of high risk bladder cancer 
patients treated with intravesical BCG (Decobert, Larue et al. 2006).  
 
Currently, many of the studies relating to the effect of genetic 
polymorphisms on the response of bladder cancer to BCG, were of small 





size are needed to validate the usefulness of gene polymorphisms to predict 
treatment outcome. There was also known differences of the effect of gene 
polymorphisms on BCG response due to ethnicity.  
 
1.3.2. Summary on BCG efficacy and response 
There are many factors that contribute to BCG failure. Also, given the 
limited overall efficacy of BCG and the difficulty with overcoming many of 
the predisposing factors (including genetic factors) that result in BCG failure, 
there is an urgent need not only to improve current therapeutic regimens but 
also to develop novel therapeutic strategies to prevent or delay disease 
progression. 
 
1.3.3. BCG and mTOR 
Recently, it has been shown that mycobacteria including BCG, can 
induce autophagy and increase mTOR activity (Zullo and Lee 2012). 
Furthermore, it has also been suggested that mTOR inhibition combined with 
BCG could enhance Th1 immune responses (Jagannath and Bakhru 2012). 
These studies suggest a rationale for investigating mTOR inhibition as a 
therapeutic option for bladder cancer patients, especially in those who are 
likely to fail or have failed BCG therapy. 
 
1.4. mTOR inhibition as a new therapeutic strategy for bladder cancer 
The mammalian target of rapamycin (mTOR) is a 290kDa serine-
threonine protein kinase. It is a key downstream protein kinase of the 





ability to integrate signals from nutrient and growth factor stimuli and govern 
protein biosynthesis, cell growth, and cell cycle progression (Fig. 1.4) (Dancey 
2006; Gomez-Pinillos and Ferrari 2012). At the beginning of this study in 
2007, little was known about the importance of the mTOR pathway in bladder 
cancer or the therapeutic use of its inhibition for the treatment of bladder 
cancer.  
 
1.4.1. mTOR pathway and function 
The mTOR protein is the catalytic subunit of two molecular 
complexes: mTORC1 and mTORC2. The rapamycin-sensitive mTOR 
complex 1 (mTORC1) contains mTOR, the regulatory-associated protein of 
mTOR (raptor), the proline-rich AKT substrate 40 (PRAS40), mLST8/G-
protein β-subunit–like protein (GβL), and deptor (Foster, Acosta-Jaquez et al. 
2010). Activated mTORC1 causes phosphorylation and inactivation of 4E-
BP1 (eIF-4E-binding protein / inhibitory binding protein) and also causes 
phosphorylation and activation of S6K1 (ribosomal S6 kinase 1) (Fig. 1.4) 
(Fasolo and Sessa 2012). S6K1 activates the ribosomal protein S6 that 
stimulates the translation of mRNA with a 5’ oligopyrimidine tract, which up 
to 30% of the mRNA that encodes many components of the protein synthesis 
machinery, including ribosomal proteins, translation initiation, and elongation 
factors (Gomez-Pinillos and Ferrari 2012). The phosphorylation of 4EBP1 
(eIF-4E-binding protein) releases eIF4E (eukaryotic initiation factor 4E), 
allowing the association of eIF4E with eIF4G to form the active eIF4F 
complex, a key component of the protein synthesis machinery that is 





(Gomez-Pinillos and Ferrari 2012). The 5’ capped mRNA then encodes 
relevant proteins for cell growth and cell cycle progression, such as growth 
factors, receptors, cyclins, c-myc, and signaling proteins. Thus activated eIF4E 
and S6K1 promote translation of mRNA and protein synthesis (Fasolo and 
Sessa 2012). Under normal physiologic conditions,  insulin / glucose, growth 
factors, availability of nutrients, oxygen, and increased intracellular levels of 
energy (high ATP concentrations), are key signals that can result in the 
activation of mTORC1, to promote ribosome biogenesis, protein synthesis, 
and angiogenesis to support cell growth and proliferation (Fig. 1.4) (Gomez-
Pinillos and Ferrari 2012). The mTOR complex 2 (mTORC2), which has only 
been recently discovered, contains mTOR, the rapamycin-insensitive 
companion of mTOR (rictor), mLST8, deptor, and the stress activated MAPK-
interacting protein 1 (Sin1) (Fig. 1.4) (Gomez-Pinillos and Ferrari 2012). 
mTORC2 is less well understood than mTORC1, but is known to 
phosphorylate serum- and glucocorticoid-regulated kinase (SGK), protein 
kinase C (PKC), and also AKT at Ser473, which in turn regulates cell cycle 
progression and cell survival (Fig. 1.4) (Gomez-Pinillos and Ferrari 2012). 
mTORC2 is also involved in actin cytoskeleton organization, and has been 
described to be rapamycin-insensitive (Fasolo and Sessa 2012; Gomez-Pinillos 








Fig. 1.4. The mammalian target of rapamycin (mTOR) signalling pathway and 
downstream effects (Gomez-Pinillos and Ferrari 2012). Figure reproduced 




1.4.2. Upstream regulation of mTOR: the PI3-AKT-mTOR pathway 
 
Phosphatidylinositol 3-kinase (PI3K) is a heterodimeric kinase 
consisting of two subunits, the p85 regulatory subunit (encoded by PIK3R1), 
which is associated with many tyrosine kinases and the p110 catalytic subunit 
(encoded by PIK3CA), which catalyses the phosphorylation of 
phosphatidilinositol-4,5-biphosphate (PIP2) to phosphatidilinositol- 3,4,5-
triphosphate (PIP3) by transferring a phosphate group from ATP (Fasolo and 
Sessa 2012). Growth factors (GF) play an important role in the regulation of 





growth factor (TGF), vascular endothelial growth factor (VEGF), hepatocyte 
growth factor (HGF), platelet-derived growth factor (PDGF), insulin-like 
growth factor 1 (IGF-1) can bind to the external domain of transmembrane 
receptor tyrosine kinases (RTKs) to activate mTOR and stimulate cell growth 
(Gomez-Pinillos and Ferrari 2012). In response to extracellular stimuli such as 
growth factors, activation of RTKs leads to auto-phosphorylation of the 
intracellular portion of these receptors, with recruitment of PI3K directly by 
the interaction between activated RTKs and the p85 regulatory subunit of 
PI3K, or indirectly by RTKs activation of RAS, which binds and activates the 
p110 subunit of PI3K (Fig.1.4) (Fasolo and Sessa 2012).  
 
The tumour suppressor phosphatase PTEN (phosphatase and tensin 
homologue deleted on chromosome 10) and other phosphatases negatively 
regulate PI3K, by reversing the action of PI3K and de-phosphorylates PIP3 to 
PIP2. PIP3 is a second messenger which recruits to the inner surface of the cell 
membrane and activates downstream effectors that involve AKT and other 
proteins (Fasolo and Sessa 2012). AKT is a serine/threonine kinase which 
when activated, can activate mTORC1 by inactivating phosphorylation of 
three negative regulators, which includes tuberous sclerosis complex (TSC), 
glycogen synthase kinase 3 beta (GSK3B) and PRAS40 (which competes with 
Rheb-dependent phosphorylation of raptor in the mTORC1 complex), and thus 
remove their inhibitory effect on mTORC1 (Fig. 1.4) (Dancey 2006; Fasolo 
and Sessa 2012; Gomez-Pinillos and Ferrari 2012). The upstream regulators of 
mTORC2 are not well known, but has been thought to be modulated by the 





mTOR are linked to each other by negative and positive feedback loops, which 
are intrinsic self- control mechanisms in the pathway (Fig. 1.4) (Dancey 2006; 
Gomez-Pinillos and Ferrari 2012). Therefore, mTOR activation may be said to 
proceed through and in parallel to PI3K and AKT (Dancey 2006). 
 
1.4.3. mTOR in cancer 
A large spectrum of molecular alterations that deregulate the mTOR 
pathway can be found in cancers (Gomez-Pinillos and Ferrari 2012). These 
changes help support the increased metabolic demands due to the high rates of 
growth and proliferation in cancer cells. The molecular alterations in human 
cancer can result in the constitutive activation of the PI3K-AKT-mTOR 
pathway, which can include loss or reduction of PTEN expression and 
function, p53 mutations, mutation or amplification of PIK3CA (p110α), 
mutation or amplification of AKT, mutation of regulatory proteins such as 
TSC1 or TSC2, overexpression or mutation of tyrosine kinase receptors 
through overexpression or increased affinity / availability of ligands, and 
mTOR downstream effectors such as S6K1 or eIF4E (Gomez-Pinillos and 
Ferrari 2012). Alterations in the crosstalk between PI3-AKT-mTOR and the 
RAS-RAF-MEK-ERK pathways is possible, contributing to development of 
cancer (Gomez-Pinillos and Ferrari 2012). However, no mutation of mTOR 
itself has ever been described (Fasolo and Sessa 2012).  
 
In recent years, mTOR, has been recognized to play a central role in 
controlling cancer cell growth (Dancey 2006). AKT and mTOR function as 





cycle, and apoptosis (Castedo, Ferri et al. 2002). Although the biochemical 
effects of mTOR signalling are still incompletely understood, the multiple 
cellular signalling processes in which mTOR participate in normal and 
malignant cells, potentially makes mTOR a prime target for therapeutic 
inhibition of cancers. 
 
1.4.4. mTOR inhibition 
Inhibition of mTOR results in a wide variety of effects on normal and 
malignant cells, including induction of apoptosis and inhibition of cell cycle 
progression, cell growth, angiogenesis, endothelial cell proliferation, and 
protein translation (Dancey 2006; Mamane, Petroulakis et al. 2006). mTOR 
also regulates endothelial cell proliferation, hypoxia inducible factor 1 and 
VEGF expression, angiogenesis, and vascular permeability, and can also serve 
to modulate the transcription of DNA to RNA (Faivre, Kroemer et al. 2006; 
Meric-Bernstam and Gonzalez-Angulo 2009). Also, while the regulation of 
autophagy remains poorly understood, there is growing evidence that mTOR 
also plays an important regulatory role in this process (Song, Ouyang et al. 
2005; Abedin, Wang et al. 2007; Yazbeck, Buglio et al. 2008). Other effects of 
mTOR inhibition include immunosuppression by inhibiting the proliferative 
responses induced by several cytokines such as IL-1, IL-2, IL-3, IL-4, IL-6, 
IGF, PDGF and colony-stimulating factors (Faivre, Kroemer et al. 2006). 
 
Rapamycin, which is derived from bacteria, was first discovered to 
inhibit the mTOR signaling pathway in the early 1990s (Gomez-Pinillos and 
Ferrari 2012). Rapamycin binds to FK506-binding protein-12, its intracellular 





phosphorylation of S6K1 and 4EBP1, its downstream targets (Sabatini 2006). 
Although the mechanism of action has not been completely elucidated, 
Rapamycin has been used as an antifungal, immunosuppressive and 
antineoplastic agent. 
 
Analogues of rapamycin, also known as rapalogues, inhibit mTOR in a 
similar manner but are more potent and increased activity in clinical use than 
rapamycin (Bartholomeusz and Gonzalez-Angulo 2012). They share the same 
mechanism of action but differ in pharmacokinetic properties. Rapalogues 
such as RAD001 (everolimus; Novartis) and AP23573 (Deforolimus; Ariad 
Pharmaceuticals) have been shown to exhibit potent preclinical activities 
against a wide variety of cancers, including rhabdosarcoma, neuroblastoma, 
glioblastoma, small cell lung cancer, renal cancer, osteosarcoma, pancreatic 
cancer, leukemias, B-cell lymphoma, and breast and colon cancer (Mamane, 
Petroulakis et al. 2006). Currently, temsirolimus and everolimus have been 
clinically approved for the treatment of metastatic renal cancer (Fasolo and 
Sessa 2011; Gomez-Pinillos and Ferrari 2012).  Everolimus has also been 
recently approved for the treatment of neuroendocrine tumours of the pancreas 
and subependimal giant cell astrocytoma (Gomez-Pinillos and Ferrari 2012). 
Other mTOR pathway inhibitors are being studied in clinical trials. 
 
Resistance to rapamycin is common, which could be due to the 
mTORC1 activation of PI3K/AKT pathway and mTORC2 signalling, through 
IRS1 (insulin receptor substrate), thus limiting its efficacy (Fasolo and Sessa 





the mTOR pathway, and rapalogues mainly inhibit mTORC1 (Fasolo and 
Sessa 2012). However, it has been shown that prolonged treatment with 
rapamycin can partially inhibit mTORC2 activity in a minority of cell lines 
possibly due to interference with the assembly of mTORC2, with subsequent 
decrease in AKT activation (Sabatini 2006; Sarbassov, Ali et al. 2006; 
Abraham and Gibbons 2007). Current development include new small 
molecule inhibitors which target both mTORC1 and mTORC2, and dual 
PI3K-mTOR inhibitors, which are small molecules which inhibit both mTOR 
and PI3K (Fasolo and Sessa 2012). In view of the known cross-talk between 
signalling pathways, another strategy is the use of other inhibitors or 
chemotherapy, in combination with mTOR inhibition to overcome treatment 
resistance. Combination therapies that are being investigated include erlotinib 
plus GDC0941 (PI3K inhibitor) for solid tumours, cetuximab plus PX866 
(PI3K inhibitor) for advanced colorectal cancer, and MK2206 (Akt inhibitor) 
plus INK128 (mTOR kinase inhibitor) plus placlitaxel (chemotherapy) for 
breast cancer (Bartholomeusz and Gonzalez-Angulo 2012). 
 
1.4.5. mTOR inhibitor therapy in bladder cancer 
 
Given the breadth of its downstream effects on cancer cells, the PI3K-
AKT-mTOR signaling pathway may represent a promising molecular target 
for bladder cancer. In support of this hypothesis, Wu et al recently showed that 
55% of human bladder tumors analyzed had increased expression of 
phosphorylated AKT (pAKT) and that inhibition of the PI3K pathway could 
drastically reduce the invasive capacity of bladder cancer cell lines (Wu, Obata 





patients with bladder transitional cell carcinoma (Wu, Obata et al. 2004). In 
addition, it has been reported that inhibition of the AKT pathway by forced 
expression of PTEN reduced the growth of bladder cancer cells, and that the 
PTEN/AKT pathway could be an important therapeutic target for bladder 
cancer (Tanaka, Koul et al. 2000). AKT, a serine-threonine kinase that is 
dependent on PI3K signaling for activation, is known to be involved in cell 
proliferation and a variety of anti-apoptotic pathways (Alessi and Cohen 
1998). Inactivation of the tumor suppressor gene PTEN, which is mapped to 
chromosome 10q23, has also been suggested to be involved in bladder cancer 
progression (Sandberg and Berger 1994; Cappellen, Gil Diez de Medina et al. 
1997; Cairns, Evron et al. 1998; Aveyard, Skilleter et al. 1999). Recently, a 
synergistic relationship between deletion of p53 and PTEN, which deregulates 
mTOR signaling was shown to promote tumourigenesis in a murine model of 
bladder cancer (Puzio-Kuter, Castillo-Martin et al. 2009), and rapamycin has 
been shown to inhibit the proliferation of bladder cancer cells in vitro 
(Fechner, Classen et al. 2009).  
 
Hansel et al evaluated the frequency of mTOR activation in a 
consecutive cohort of 121 muscle-invasive and 40 non-muscle invasive 
urothelial cancers (Hansel, Platt et al. 2010). They reported that the expression 
of phosphorylated mTOR (p-mTOR) and the downstream target, ribosomal S6 
protein (PS6), was identified in 74% (90/121) and 55% (66/121) of muscle-
invasive urothelial cancers obtained from cystectomy specimens, respectively, 
and that there was no significant difference in expression between non-





found to be present in approximately 50% and 36% of cells respectively, in the 
NMIBC group (Hansel, Platt et al. 2010). The authors concluded that the 
frequent expression of p-mTOR and p-S6 in bladder cancer specimens 
suggested that a large proportion of patients would have increased activity of 
the mTOR signalling cascade, with the potential to respond to mTOR inhibitor 
therapy. Furthermore, it was suggested that because mTOR activity occurred 
in many cases of non-muscle invasive low and high grade urothelial cancers, 
the activation of mTOR pathway may be a relatively early step in urothelial 





1.5. Aims of this study 
 
 
The aim of the first part of the study is to determine the predictive 
value of NRAMP1 and hGPX1 gene polymorphisms for cancer recurrence and 
response to intravesical BCG immunotherapy, in high risk NMIBC patients. 
This is in the effort to determine some of the underlying reasons for BCG 
failure, and also to identify those bladder cancer patients who are unlikely to 
respond and benefit from BCG immunotherapy. 
 
The aim of the second part of the study is to investigate the effect of 
the mTOR inhibiton on bladder cancer cells in vitro, including its therapeutic 
efficacy and downstream effects, and to verify its effects in vivo using an 
animal model. The mTOR inhibitor RAD001 was investigated in an effort to 
explore the use of mTOR inhibition as a possible new therapeutic strategy for 
bladder cancer therapy. 
 
The aim of the final part of the study is to evaluate firstly, methods of 
enhancing the therapeutic effect of mTOR inhibition on bladder cancer cells 
through combination with other modalities of treatment (such chemotherapy 
and other inhibitors), and secondly, alternative strategies to maintain efficacy 


































Chapter  2 































2.0. Chemicals and Reagents 
 




NcoI, AvaII, ApaI, EcoR1 and BglII 
Promega USA 
Transfast transfection reagent 
 
Eagle’s minimum essential medium Mediatech Inc USA 
L-glutamine Sigma-Aldrich USA 








Luria Broth (LB) medium 
Autophagic inhibitors 3-Methyladenine, 







GE Healthcare USA 
[3H]thymidine  MP Biomedicals USA 
Dulbecco's modified Eagle's medium 
without l-glutamine and leucine 
 
QIAamp DNA mini kit, Endofree Maxi 
QIAGEN plasmid purification kit 
 
QIAGEN USA 







(Thr 389), p70S6K, anti-phosphorylated-
mTOR (Ser 2448), mTOR (Ser 2448) and 
anti-phosphorylated-4EBP1 (Ser 65), anti-
phosphorylated-AKT (Ser 473) antibodies 
Cell Signaling USA 
SiRNA targeting mTOR 
 




















EMD Biosciences USA 




















Primers for NRAMP1 D543N and (GT)n, 
and hGPX1 



































2.1. Section I: Single Nucleotide Polymorphism Genotyping 
 
2.1.1. DNA Extraction and Polymerase chain reaction (PCR) 
DNA was extracted using a mini-blood kit (QIAGEN, USA). Table 2.1 lists 
the primers (1st base, Singapore) used for NRAMP1 and hGPX1 PCR 
(Eppendorf Master cycler, Germany) and the expected size after enzyme 
digestion. The fluorescent primers were from Applied Biosystems, USA. 
Annealing temperatures (Tm), were calculated for each primer sequence to 
minimize non-specific binding, using the following formula 
(http://www.promega.com/techserv/tools/biomath /calc11.htm): 
Tm =  64.9°C + 41°C x (number of G’s and C’s in the primer – 16.4)/N 
(where N is the length of the primer) 
2.1.2. Restriction fragment length polymorphisms (RFLP) and DNA 
sequencing  
For RFLP, the PCR products were digested with the restriction enzymes 
(Promega, USA) overnight at 37°C and the end product were separated on a 
3% agaraose gel (Table 2.1).  The analysis of the (GT)n genotype digested 
products, was performed on a ABI PRISM 310 genetic analyzer (Applied 
Biosystems) in duplicate using GeneScanTM-500 ROX (Applied Biosystems) 
as an internal standard. Data was analyzed using GeneScan Analysis software 








Table 2.1. Single nucleotide polymorphism genotyping primers and conditions 
(Liu, Fujiwara et al. 1995; Zhao, Liang et al. 2005). 
 
Gene 






















94°C for 5 min;  
35 cycles at 94°C 
for 30 s, 51°C for 
30 s, and 72°C for 
30 s; final 
extension at 72°C 
for 5 min 
NcoI  3 allele = 286, 









94°C for 5 min; 35 
cycles at 94°C for 
30 s, 54°C for 30 
s, and 72°C for 30 
s; final extension 
at 72°C for 5 min 
AvaII  Allele A = 201 
and 39 bp  
Allele G =  126, 






94°C for 5 min; 35 
cycles at 94°C for 
30 s, 54°C for 30 
s, and 72°C for 30 
s; final extension 
step at 72°C for 5 
min 
ApaI  CC genotype = 
195, 117, and 
88 bp 
CT genotype = 
205, 195, 117 
and 88 bp 
TT genotype = 
205 and 195 bp 
 
2.1.3. Statistical analysis 
Analyses were performed using SPSS 17.0 with statistical significance set at 
p<0.05. Univariate analysis (Chi-square test / Fischer’s exact test)  and 
multivariate analysis (logistic regression) were used to correlate genotypes 
with patient and tumour characteristics, recurrence, stage progression, cancer 
specific and non-cancer specific death, overall, as well as stratified by 
treatment arm. Time to recurrence, progression, and the disease-specific 
survival time were analyzed using the Kaplan–Meier method and adjusted for 
relevant covariates using cox regression (multivariate analysis). 
 





Cross-contamination of cell lines is a serious but often unrecognized problem. 
The panel of bladder cancer cell lines were authenticated using the short 
tandem repeat (STR) profiling technique to detect cross-contamination, prior 
to experiments. 
 
2.2.1. Growth and maintenance of bladder cancer cell lines 
The transitional cell carcinoma cell lines UM-UC-1, UM-UC-2, UM-UC-3, 
UM-UC-6, UM-UC-9, UM-UC-10, UM-UC-11, UM-UC-13, UM-UC-14, 
UM-UC-16, T24 and KU7 were obtained at source (Grossman H.B., The 
University of Texas MD Anderson Cancer Center, Houston, Tx, USA) from 
cryopreserved cells frozen over a span of more than 25 years (Grossman H.B., 
The University of Texas MD Anderson Cancer Center, Houston, Tx, USA). 
UM-UC-3 was also obtained from the American Type Culture Collection 
(ATCC; Manassas, VA, USA). The cells were maintained in Eagle’s minimum 
essential medium (Mediatech Inc., Herndon, VA, USA) supplemented with 2 
mM L-glutamine, 10% heat-activated fetal bovine serum, 100 U/ml penicillin, 
and 100 µg/ml streptomycin. The prepared media was stored at 4C. The cell 
lines were grown in plastic flasks at 37C in a humidified chamber with 5% of 
CO2.  Cells were passed with 0.25% trypsin in Hanks media (Sigma-Aldrich, 
St. Louis, MO, USA) when confluent. All cultures were free of bacterial, 
fungal, and mycoplasma contamination.  
 
2.2.2. DNA Extraction and Sequencing 
Genomic DNA was isolated from 2 x 106 cells using a QIAamp DNA mini kit 





was used for STR profiling. DNA concentration was determined by light 
absorption at 260 nm. DNA samples from the cell lines were also sent for 
sequence analysis for the p53 gene. 
 
2.2.3. STR Amplification and Typing 
STR loci and a segment of the X-Y homologous gene amelogenin were 
amplified using the AmpFlSTR Profiler Plus (detecting D3S1358, vWA, FGA, 
TH01, TPOX, CSF1PO, D5S818, D13S317, and D7S820 loci and 
amelogenin) and COfiler (detecting D3S1358, D16S539, TH01, TPOX, 
CSF1PO, and D7S820 loci) PCR amplification kits (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturers’ instructions in the 
GeneAmp PCR system 9700 (Applied Biosystems). Electrophoretic analysis 
was carried out using an ABI PRISM 310 genetic analyzer performance 
optimized polymer 4 (POP-4TM; Applied Biosystems) with ABI PRISM1 310 
Genetic Analyzer (Applied Biosystems). The amplified DNA fragment lengths 
were determined by comparing them with an internal size standard 
GeneScanTM-500 ROX (Applied Biosystems). Each electrophoretic run was 
analyzed with the GeneScan Analysis software v.3.1.2 (Applied Biosystems) 
and compared with AmpFlSTR1Profiler Plus allelic ladders (Applied 
Biosystems). Each experiment was repeated at least once. 
 
2.2.4. Results of STR typing 
It was shown that all cell lines had a unique STR profile except UMUC-2 and 
T24, which were virtually identical (Fig. 2.1). T24 STR profiles matched those 





fluorescence protein marker gene did not alter the STR profiles of cell lines. It 
was concluded that STR profiling provides a unique genetic signature of 
human cell lines that does not significantly change with passage or green 
fluorescence protein transduction. DNA fingerprinting using STR profiling is 
































Fig. 2.1. STR profiles of distinctly different bladder cancer cell lines at high 
(HP), intermediate (IP) and low (LP) passages. Black, Blue and Green 









2.3. Section III: Tissue Culture and in vitro mTOR targeted therapy 
2.3.1. Growth and maintenance of bladder cancer cell lines  
The characteristics of the transitional cell carcinoma cell lines UM-UC-3, UM-
UC-6, UM-UC-9, and UM-UC-14 are summarized in Table 2.2. The cell lines 
were authenticated within 6 months of performing the experiments (Chiong, 
Dadbin et al. 2009). For maintenance, cells were passaged when confluent, 
about every 4-5 days, using 0.25% trypsin in Hanks media (Sigma-Aldrich, St. 
Louis, MO, USA). Cells were dislodged using trypsin and single cell 
suspension achieved by repeated pipetting of cells in media. Cells were plated 
in varying concentrations on six-well plates and incubated up to 6 days to 
determine optimal number of cells to avoid being over-confluent at day six, in 
order to perform in vitro experiments. 
 
 
Table 2.2. The characteristics of p53, PTEN, and pAKT expression in bladder 




2.3.1. Reagents and drug preparation  
RAD001 and placebo were obtained from Novartis Pharma AG (Basel, 
Switzerland). The RAD001 stock (20 mM, molecular weight of 958.25) was 
diluted with media with Dimethyl sulfoxide (DMSO) (0.05%) and aliquoted in 
Cell Lines TP53 PTEN pAKT 
UM-UC-3 mutated mutated increased expression 
UM-UC-6 wild type wild type decreased expression 
UM-UC-9 mutated decreased expression increased expression 





concentrations of 100 nM and stored at -80C. For the in vitro experiments, 
RAD001 was prepared in DMSO and in reduced light conditions, due to light 
sensitivity of RAD001. 
 
2.3.2. In vitro cell growth: Crystal violet assay  
Cell growth was measured using a crystal violet assay as previously described 
(Kanamaru and Yoshida 1989). Bladder cancer cells were plated into six-well 
plates at a density of 1.25 × 104 cells/well. After 24 hours, the cells were 
treated with one of six concentrations of RAD001 (0.1, 0.5, 1, 10, 20, or 
100 nM) and incubated at 37C in a humidified chamber with 5% of CO2. 
After 4 and 6 days of exposure to either RAD001 or the control (DMSO 
0.05%), the medium was removed, and the cells were fixed with 1% 
glutaraldehyde for 15 min and stained with 0.5% crystal violet. The dye was 
eluted with Sorenson's buffer (6.1 ml of 0.1 M disodium citrate, 3.9 ml of 0.1N 
HC1, and 10 ml of 95% ethanol). The eluted material was transferred to a 96-
well plate, and the optical density was read on a microplate autoreader (Bio-
Tek Instruments, Winooski, VT, USA) at 540 nm. The optical density values of 
the RAD001-treated cells were normalized to the values obtained for the 
DMSO-treated control cells to determine the percentage of surviving cells. For 
the re-dosing experiments, the cells were retreated 3 days after the initial 
treatment with the IC50 dose of RAD001. Each assay was performed in 
duplicate and the experiments were repeated twice. 
 
2.3.3. In vitro cell proliferation: [3H]thymidine incorporation assay 





cells/well. After 24 hours, the cells were treated with one of five 
concentrations of RAD001 (0.1, 0.5, 1, 10, or 100 nM). After 48 hours of 
exposure to either RAD001 or the control or DMSO, the medium was 
removed and replaced with fresh cell culture medium containing 1% fetal 
bovine serum and 10 μCi/mL [3H]thymidine (MP Biomedicals, USA). The 
cells were pulsed with [3H]thymidine for 2 hours and the media was 
subsequently removed.  Cells were then lysed by the addition of 0.1 mol/L 
KOH and harvested onto fiberglass filters. The incorporated tritium was 
quantified in a scintillation counter (1450 MICROBETA Trilux liquid 
scintillation and luminescence counter; PerkinElmerTM life sciences). Each 
assay was performed in duplicate and the experiments were repeated once. The 
[3H]thymidine incorporation was expressed as a percentage of the control 
which consisted of untreated cells. The percentage of incorporation was 
calculated as follows:  
[(cpm of RAD001 treated cells – background cpm) ÷ (cpm of untreated cells – 
background cpm)] x 100% 
 
2.3.4. Flow cytometry 
Bladder cancer cells were grown in six-well plates and after reaching 70% 
confluence, they were exposed to various concentrations of RAD001 as 
described in the previous section, for 24, 48, and 72 hours. Cells from the 
media were collected and attached cells were harvested by rinsing with 
phosphate-buffered saline (PBS) and trypsin digestion. The cell suspension 





The pellets were then re-suspended in phosphate-buffered saline containing 50 
µg/mL propidium iodide (PI), 0.1% Triton X-100, and 0.1% sodium citrate. 
DNA staining with PI was measured by fluorescence-activated cell sorting 
analysis using the FL-3 channel (FACS Calibur flow cytometer, Becton 
Dickinson, CA, USA) to determine the cell cycle distribution, measuring at 
least 10,000 gated cells. Cells displaying a hypodiploid DNA content, which is 
indicative of DNA fragmentation, were scored as apoptotic. PI exclusion was 
performed in a similar fashion 24 and 48 hours after RAD001 exposure, 
without the addition of 0.1% Triton X-100. Annexin V-fluorescein 
isothiocyante and PI flow cytometry were performed following the 
manufacturer’s instructions (TACS Annexin V-FITC Apoptosis Detection Kit 
from Trevigen, Gaithersburg, MD, USA) as follows: detached cells were 
collected by centrifugation and attached cells harvested by trypsinization. 
They were washed in cold PBS, adjusted to 5×105 cells/ml and pelleted by 
centrifugation. Cell pellets were then resuspended in 100 μl of Annexin V 
incubation reagent (1 μl of annexin V-FITC, 10 μl of PI, 10 μl of 10X binding 
buffer, and 79 μl of deionized distilled water). The mixture was incubated for 
15 minutes at room temperature in the dark. Diluted 1X binding buffer (400 
μl ) was then added to each sample and analyzed by PI flow cytometry within 
1 hour. 
 
2.3.5. Preparation of cell lysates  
24 to 48 hours after treatment, media from plates of the RAD001 treated cells 
and the control cells were aspirated. The cells were washed with 2 ml of ice-





µl cell lysis buffer [comprising Tris-HCL 20 mM (pH 7.5), aprotinin 2 µg/ml, 
leupeptin 5-10 µg/ml, pepstatin A 1 µg/ml, phenylmethylsulfonyl fluoride 1 
mM, EDTA 5 mM, EGTA 1 mM, sodium fluoride 5-10 mM and sodium 
orthovanadate 1 mM] and the cells were dislodged by scrapping, while placing 
the 6-well plate on ice for 15 minutes. The extracts were transferred into 
microcentrifuge tubes. Then the extracts were centrifuged for 3 min at 
maximum speed at room temperature and the supernatant was transferred to 
new microcentrifuge tube. The lysates were stored at -80C till assayed for 
enzyme activity. 
 
2.3.6. Protein assay 
Protein concentration was estimated using Pierce’s BCA Protein Assay 
Reagent Kit. In brief, 20 times dilutions of each of the lysates were prepared 
by adding 5 μl of lysate to 95 μl of PBS. A set of BSA standards was prepared 
as described in the Pierce’s BCA Protein Assay Reagent. Then 100μl of BCA 
Working Reagent (WR) was added to each of the diluted samples and BSA 
standards followed by incubation with shaking for 30 min. The mixture was 
transferred to a separate cuvette and the absorbance measured using a 
spectrophotometer at 562 nm, with the lysis buffer control as blank. The 
protein concentration was calculated from the standard curve.  
 
2.3.7. Western blot analysis 
Cells were harvested at 70% to 80% confluence and cell lysates were obtained 
as previously described. Protein extracts (30 to 50 µg/lane) were 





transferred onto nitrocellulose membranes (Tanaka, Koul et al. 2000). The 
nitrocellulose membranes were incubated with 1:200 to 1:1,000 dilutions of 
primary antibodies, followed by a horseradish peroxidase–linked secondary 
antibody (antirabbit 1:3,000 or antimouse 1:5,000). The antibody-probed 
proteins were detected using an enhanced chemiluminescence kit (Amersham 
Biosciences) according to the manufacturer's instructions. Anti-phosphorylated 
(phospho)-p70S6K (Thr 389), p70S6K, anti-phosphorylated-mTOR (Ser 
2448), mTOR (Ser 2448) and anti-phosphorylated-4EBP1 (Ser 65) antibodies 
were purchased from Cell Signaling. The secondary antibodies were purchased 
from Santa Cruz Biotechnology, and the anti-actin antibody was purchased 
from EMD Biosciences. A cell line from another organ system was used as a 
positive control. 
 
2.3.8. Protein synthesis assay 
The bladder cancer cells were plated into six-well plates at a density of 1 × 105 
cells/well. The radiolabeled protein–uptake assay was performed as previously 
described (Poole and Wibo 1973). After 24 hours, the cells were treated with 
various concentrations of RAD001. After 2 and 12 hours of exposure to either 
RAD001 or control (DMSO), the medium was removed, 2 μCi/ml of L-[4,5-
3H]leucine (GE Healthcare, Piscataway, NJ, USA) and leucine-free media 
(Dulbecco's modified Eagle's medium without l-glutamine and leucine, MP 
Biomedical, Irvine, CA, USA) supplemented with 20 ml/L of 200 mM L-
glutamine and 110 mg/L of sodium pyruvate were added, and the cells were 
incubated at 37C in a humidified chamber with 5% CO2, for 2 hours. The 





were then dislodged from the wells by 0.25% trypsin digestion, pelleted by 
centrifugation, transferred to eppendorf tubes, where 100μl of lysis buffer was 
added and incubated for 1 hour at 4C. The supernatant was then separated by 
centrifugation. Within each tube, 20 μl of the supernatent was mixed with 
0.5ml of cold 10% trichloroacetic acid (TCA). The solution was incubated 
with shaking for 20 minutes at 4C. The protein extracts were pelleted by 
centrifugation and the supernatant was discarded. This was mixed with 200 μl 
of cold 0.1M potassium hydroxide (KOH) to dissolve the pellet. The 
radioactivity of the solution was measured as disintegrations per minute 
(DPM) using a liquid scintillation counter (Beckman LS 6500, Global Medical 
Instrumentation, Inc.). Cycloheximide 40uM (12 ug/ml) which is a known 
protein synthesis inhibitor was used as a positive control. All experiments 
were performed in triplicate and repeated once.  
 
2.4. Section IV: Animal studies 
2.4.1. Animal model 
 
All animal experiments were conducted according to institutional guidelines 
established for the Animal Core Facility at The University of Texas M. D. 
Anderson Cancer Center, USA. The animal model was first established to 
determine the optimal number of cells needed to implant in the nude mice to 
allow the tumours to grow over a period of 4 weeks. Cells were grown in 
flasks till 85% confluence and passaged. The mice were anaesthetized by 
intraperitoneal injection of 0.1 ml of anaesthetic cocktail. Varying number of 
cells (5x 105, 1x 106, 2x 106 cells in 100µl of media suspension) were injected 





(nu/nu; Harlan, Indianapolis, IN, USA), within 1 hour 20 minutes of the cell 
harvesting. The injections were achieved by instilling 100 µl of cell 
suspension subcutaneously using a 22-gauge needle. UM-UC-3 and UM-UC-6 
cells were each implanted into three mice. Tumour growth and mice well-
being was monitored twice per week for a period of at least 3 weeks. Training 
on the method of oral gavage was also performed. 
 
2.4.2. Histological confirmation 
The mice were sacrificed on day 21 to day 28 after tumour cells’ implantation.  
The tumours were removed, fixed in 10% buffered formalin and embedded in 
paraffin. 6 μm sections were cut for Hematoxylin & Eosin (H&E) staining. 
The sections were then inspected for tumor incidence, size and histology. 
 
2.4.2.1. Preparation of Silanized Slides 
Slides were dipped in 2% silane (3,aminopropyltriethoxysilane, 
Sigma)/acetone solution for 1 minute followed by 1 minute in 100% acetone. 
The slides were then washed in double distilled water for one minute.  After 
which, the slides were dried in the oven overnight and stored at room 
temperature before use. 
 
2.4.2.2. Hematoxylin & Eosin (H&E) Staining of slides 
Firstly, slides are deparaffinized in xylene and rehydrated in graded ethanol. 
The slide sections were then slightly overstained with hematoxylin for usually 





They were then differentiated and destained for a few seconds in acidic 
alcohol for four to five dips. The slides were rinsed briefly in tap water to 
remove the acid. The slides were placed in 0.1% bicarbonate until the nuclei 
would stand out sharply blue in colour, for about 2 minutes. Rinsing in 
running tap water for 8 minutes was performed. The slides were placed in 
Eosin solution for 3 minutes. Slides then taken through three changes of 95% 
ethanol, for 5 minutes each. The slides were then dehydrated and cleared, 
following which the sections could be mounted.  
 
2.4.3. Drug preparation and administration for animal studies 
For animal studies, RAD001 and placebo were obtained from Novartis Pharma 
AG (Basel, Switzerland). RAD001 was prepared at 2% (w/w) (20 mg/g) in a 
microemulsion vehicle, which was diluted in 5% glucose in double-distilled 
water just before administration by oral gavage. Oral gavage was performed 
using an 18-gauge rigid feeding needle with a rounded tip (Popper & Sons, 
Inc). 
 
2.4.4. In vivo treatment with RAD001 
UM-UC-3, UM-UC-6, and UM-UC-9 cells (1 x 106) were injected 
subcutaneously into the right flank of 4- to 6-week-old female nude mice. Four 
to Five mice were used in each treatment group. The viability of the bladder 
cancer cells was determined by trypan blue exclusion just before injection. 
Tumour growth was measured with calipers twice per week. The tumour 
volume was calculated according to the following equation: volume (mm3) = 
length x width2 x 0.5236. When the tumours reached approximately 5 mm in 





gavage at a dose of 5 mg/kg in 100 μl 5% glucose in water or a placebo 
(Novartis Pharma AG) twice weekly for 1 month or until the tumour burden 
(approximately 1.5 cm in size) required euthanasia (anesthetized with CO2 and 
euthanized by cervical dislocation). Harvested tumour specimens were divided 
into two groups and either 1) fixed in 10% buffered formalin and paraffin-
embedded or 2) embedded in OCT and frozen in liquid nitrogen. All 
experiments were repeated once. 
 
2.4.5. Immunohistochemistry 
Paraffin-embedded tissue sections were incubated in citrate buffer, pH 6.0, at 
100°C for 20 min for antigen retrieval. The Lab Vision Autostainer (Lab 
Vision Corp., Thermo Fisher Scientific) was used for staining the samples with 
diaminobenzidene. Anti–phosphorylated-p70S6K (Thr 389) (Epitomics) 
(species reactivity: human and mouse), anti-CD31 (Lab Vision Corp., Thermo 
Fisher Scientific) (species reactivity: human), anti-VEGF (Lab Vision Corp., 
Thermo Fisher Scientific) (species reactivity: human), anti-phosphorylated-
AKT (Ser 473) (Cell Signaling) (species reactivity: human, mouse, rat, 
hamster, monkey, D. melanogaster, bovine and zebrafish), and anti-
phosphorylated-mTOR (Ser 2448) (species reactivity: human, possibly mouse 
and rat) antibodies (Cell Signaling) were used for immunohistochemical 
analyses. Negative control experiments were performed in the absence of the 
primary antibody. Tumour tissue sections from all three implanted cell lines 
were concurrently incubated with each type of antibody and stained with the 
autostainer. Additional tumor tissue sections from each cell line were used for 





tissue specimens were evaluated by light microscopy, and the immunostaining 
was scored by two independent observers who were blinded to which samples 
(i.e., drug-treated or placebo) they were evaluating. Only cytoplasmic staining 
was considered for scoring. The staining intensity was assigned a score for the 
most dominantly stained area and this stained area should occupy at least 20% 
of the specimen. The intensity of staining was scored on a scale of 0 to 3+, 
with 0 for no staining, 1+ for weak staining intensity, 2+ for moderate staining 
intensity, and 3+ for the most intense staining (see Fig.2.2 for examples of 
staining intensity scoring in various cell lines). The microvessel density was 
measured by microscopy at 100X magnification by counting the number of 
blood vessels (stained with anti-CD31) in each of five fields per tumour 
sample to obtain an average measurement (Sasaki, Nakamura et al. 2008). The 
fields with the highest density of blood vessels on the slide were selected for 
analysis. The CD31 expression data were analyzed with repeated measures 
analysis of variance. Statistical significance was determined to be p < 0.05.  
 
 
2.4.6. Statistical analysis 
The results of the statistical analyses are presented as means + standard 
deviation. Differences between the groups were tested by using the unpaired 
Student t test. All p values were two sided, and a p value of less than 0.05 was 















Fig. 2.2. Immunohistochemical staining of representative implanted tumour 
tissue sections harvested after prolonged treatment with RAD001. Examples 
of staining intensity (1+, 2+ or 3+) for phospho-mTOR (in UM-UC-9 
implanted tumour), phospho-p70S6K and phospho-AKT (in UM-UC-6 
implanted tumour) are shown at 400X magnification. No figure is shown if the 






















2.5. Section V: Autophagy, oxidative stress and membrane effects of 
mTOR therapy 
2.5.1. Transmission Electron Microscopy (TEM) 
5 x 105 UM-UC-6 and UM-UC-9 cells per well were plated to achieve about 
70-80% confluence at day 1 after treatment. The cells were then treated with 
control DMSO or RAD001 at 100 nM. The media was then removed after 12 
or 24 hours and cells washed with PBS, fixed and stored at 4C. TEM of cells 
was then performed in the High Resolution Electron Microscopy Facility in 
University of Texas MD Anderson Cancer Center, Houston, Tx, USA, to 
identify autophagy markers. Digital images were obtained using the AMT 
Imaging System (Advanced Microscopy Techniques Corp., Danvers, MA, 
USA). 
 
2.5.2. Green Fluorescence Protein (GFP)-LC3 
The plasmid pEGFP-C1 containing the LC3 (microtubule-associated protein 1 
light chain 3; which is a mammalian homolog of yeast Atg8) construct (Fig. 
2.3) was obtained from the Urology laboratory of the The University of Texas 
MD Anderson Cancer Center, Houston, Tx, USA. The transfection reagent 








Fig. 2.3. Plasmid pEGFP-C1 containing the LC3 construct 
 
2.5.2.1. Production of plasmid DNA for transfection 
2.5.2.1.1. Preparation of competent E. coli 
A single colony of E. coli was used to inoculate a starter culture consisting of 
10ml Luria Broth (LB) medium. The culture was grown overnight at 37C 
with vigorous shaking at 200 rpm. To set up the large culture, 2ml of the 
starter culture was used to inoculate 200ml of LB medium in a sterile flask. 
The culture was allowed to grow at 37C with vigorous shaking at 200 rpm 
until an OD600 of 0.4 (about 2-3 hours). The culture was then transfer to four 
50ml centrifuge tubes and placed on ice for 10 min before centrifuged at 3000 
x g (Beckman JA-14 rotor), 4C for 10 minutes. The supernatant was 





containing 15% glycerol. The cells were stored at -80C until required.  
 
2.5.2.1.2. Transformation of plasimds 
1 g of plasmid DNA was mixed with 1xTE buffer (10mM Tris-HCL, 1mM 
EDTA, pH 8.0) to a volume of 20l in a sterile 1.5 ml tube and stored on ice. 
Frozen competent cells were thawed rapidly by warming between hands and 
100l of cells was dispensed into each tube. Tubes were gently swirled to mix 
contents and stored on ice for 10 min. Tubes were then transferred to a  42 C  
water bath and heat shocked for 45 sec  following which tubes were left at 
room temperature for 10 min. 400l of LB medium was added and the cells 
were placed in a 37 C water bath for 30 min. 100l of the transformed 
competent cells were then transferred to LB plates containing 20g/ml of 
kanamycin or other appropriate antibiotics and gently spread using a sterile 
glass spreader.  Once all liquid was absorbed, the plates were inverted and 
incubated at 37C overnight until colonies are found. 
 
2.5.2.1.3. Preparation of endotoxin-free plasmid DNA for transfection 
The Endofree Maxi QIAGEN plasmid purification kit was used for the 
isolation of the plasmid DNA used for transfection. A single colony was used 
to inoculate a starter culture consisting of 5ml LB medium containing 20g/ml 
of kanamycin or other antibiotics. The culture was grown for 8 hours at 37C 
with shaking at 200 rpm.  Then the starter culture was diluted into 100ml of 
LB medium containing antibiotics and was grown overnight at 37C. The cells 





min) and the bacterial pellet was resuspended in 10ml of Buffer P1 (50mM 
Tris-HCL (pH 8), 10mM EDTA and 100g/ml Rnase A). Bacterial cells were 
lysed with 10 ml of Buffer P2 (200mM of NaOH and 1% SDS). After gentle 
mixing, 10 ml of Buffer P3 (3M potassium acetate pH 5.5) was added and 
mixed by inversion. The cell debris and chromosomal DNA were removed by 
filtering. To remove endotoxins, 2.5ml of ER buffer was added to the filtered 
lysated and incubated on ice for 30 min. The lysate was then loaded onto a 
pre-equilibrated QIAGEN column by gravity flow. The salt and pH conditions 
of the lysate and the selectivity of the resin ensure that only plasmid DNA 
binds to the column. The column is then washed with Buffer QC (1M NaCl, 
50mM MOPS, pH 7 and 15% isopropanol) twice. The plasmid DNA was 
eluted with a high salt buffer QN (1.6M NaCl, 50mM MOPS, pH 7 and 15% 
isopropanol). The eluted DNA was precipitated with 10.5ml of isopropanol 
and followed by centrifugation (14000 x g, Beckman JA-20 rotor, 4C, 30 
min). The pellet was washed with 70% endotoxin free ethanol and then 
centrifuged again at 4C for 10 min (14000 x g, Beckman JA-20 rotor). The 
purified DNA was briefly air-dried and dissolved in appropriate volume of 
endotoxin free TE buffer (10mM Tris-HCl, 1mM EDTA). DNA concentration 
was estimated by measuring optical density (OD) with a spectrophotometer. 
 
2.5.2.1.4. Restriction enzyme analysis 
Presence of LC3 DNA was checked using restriction enzyme analysis. Plasmid 
was digested with the restriction enzymes EcoR1 and BglII (Promega, USA) 
overnight at 37°C and the end product were separated on a 1% agarose gel, 






2.5.2.2. Identification of autophagic markers using GFP-LC3 transfection 
The autophagic inhibitors 3-Methyladenine (3MA) and LY29004 were 
purchased from Sigma (St Louis, MO, USA). Drugs were filtered through a 2 
µm-pore filter prior to cell treatment. 2 µg of plasmid DNA was transfected 
into bladder cancer cells UM-UC-6 and UM-UC-9 using the transfection 
reagent Transfast, according to manufacturer’s protocol (Promega). Cells were 
inspected using fluorescence microscopy at 48 hours to observe for 
fluorescence from GFP. Positive control using plasmid containing GFP and 
without LC3, was used to verify transfection. Cells were then treated with 
RAD001 (for 24, 48, 72 hours or with re-treatment at 4 days), LY29004, 3-MA 
or their combination, and viewed for GFP-LC3 punctuation/aggregation using 
fluorescence microscopy. Fluorescence imaging was performed and digitally 
captured using an OLYMPUS inverted fluorescence microscope. Experiment 
was done in duplicates and was repeated. For each group, the GFP-LC3 puncta 
in each cell were manually counted. At least 100 cells were counted in each 
group for the average number of GPF-LC3 puncta / cell. 
 
 
2.5.3. Measurement of intracellular Reactive Oxygen Species (ROS) 
The cell-permeable dye CM-H2DCFDA (Molecular Probes, Life 
Technologies, Carlsbad, California, USA) was used to assay intracellular ROS 
levels. This dye diffuses into cells and is trapped inside the cell by de-
esterification. After reaction with peroxides, the fluorescent product 5-
chloromethyl-2’-7’-dichlorofluorescein (DCF) is formed. CM-H2DCFDA was 





peroxide (as positive control) were optimised prior to performing experiments. 
After exposure to RAD001 or control DMSO for 6 and 12 hours, UM-UC-6 
and UM-UC-9 cells were incubated in 2 ml of media containing 5 μM CM-
H2DCFDA for each well of the 6-well plates, at 37°C for 60 minutes in the 
dark. Media containing DMSO and 3 μM hydrogen peroxide was used as 
negative and positive controls respectively. Media was removed and cells 
dislodged with 0.25% trypsin and pelleted with centrifugation for 4 minutes, 
4°C at 1500rpm. The supernatant was removed and pellet washed with PBS 
twice by re-suspension and centrifugation as described above, to remove 
unreacted dye. Pelleted cells were finally re-suspended in 500 μl of PBS and 
200 μl from each sample was transferred to a 96-well plate. Fluorescence 
intensity was read by flow cytometry on the FL-1 (DCF) channel of a 
Beckman Coulter flow cytometer (Cell Lab Quanta SC MPL), and analyzed 
using Cell Lab Quanta Software. Experiment was done in duplicates and was 
repeated. 
 
2.5.4. Measurement of changes in mitochondrial membrane potential 
The steady state mitochondrial electrical potential of cells were assessed by 
means of the fluorescent cationic dye Rhodamine-123 (Life Technologies, 
Carlsbad, California, USA), which distributes electrophoretically into the 
mitochondrial matrix in response to the electrical potential across the inner 
mitochondrial membrane. The dose of Rhodamine-123 and hydrogen peroxide 
(as positive control) were optimised prior to performing experiments. After 
exposure to RAD001 or control DMSO for 12 and 24 hours, UM-UC-6 and 





Rhodamine-123 for each well of the 6-well plates, at 37°C for 60 minutes in 
the dark. Media containing DMSO and 3 μM hydrogen peroxide was used as 
negative and positive controls respectively. Media was removed and cells 
dislodged with 0.25% trypsin and pelleted with centrifugation for 4 minutes, 
4°C at 1500rpm. The supernatant was removed and pellet washed with PBS 
twice by re-suspension and centrifugation as described above, to remove 
unreacted dye. Pelleted cells were finally re-suspended in 500 μl of PBS and 
200 μl from each sample was transferred to a 96-well plate. Fluorescence 
intensity was read by flow cytometry on the FL-1 (DCF) channel of a 
Beckman Coulter flow cytometer (Cell Lab Quanta SC MPL), and analyzed 
using Cell Lab Quanta Software. Experiment was done in duplicates and was 
repeated. 
 
2.6. Section VI: Alternative or enhancing mTOR targeted therapy 
 
2.6.1. Autophagic inhibitor Treatment 
2.6.1.1. Reagents and drug preparation  
The autophagic inhibitors 3MA and chloroquine diphosphate were purchased 
from Sigma (St Louis, MO, USA). Chloroquine was diluted with sterile water 
and aliquoted in 10 mM portions. Drugs were filtered through a 2 µm-pore 
filter prior to cell treatment. 
 
2.6.1.2. In vitro cell growth with combination drug treatment 
Bladder cancer cells UM-UC-6 were treated with varying concentrations of 
Chloroquine (0, 5, 10, 25 and 50 µM) alone or pre-treated 1 to 3 hours before 
and  in combination with RAD001 (0, 0.5 and 100 nM) and incubated at 37C 





varying concentrations of Chloroquine (0, 2.5, 5, 10 and 50 µM) alone or pre-
treated 1 to 3 hours before and in combination with RAD001 (0, 10 and 100 
nM) and incubated at 37C in a humidified chamber with 5% of CO2. After 
4 days of exposure, the medium was removed, and the cells were fixed with 
1% glutaraldehyde for 15 min and stained with 0.5% crystal violet.  Bladder 
cancer cells UM-UC-6 were treated with varying concentrations of 3MA (0, 
2.5, 5 and 10 mM) alone or pre-treated with 2.5 -5 mM, 1 hour before and in 
combination with RAD001 (0, 0.5 and 100 nM) and incubated at 37C in a 
humidified chamber with 5% of CO2. UM-UC-9 was also treated with varying 
concentrations of 3-MA (0, 2.5, 5 and 10 mM) alone or pre-treated with 2.5 -
5mM, 1 hour before and in combination with RAD001 (0, 10 and 100 nM) and 
incubated at 37C in a humidified chamber with 5% of CO2. After up to 4 days 
of exposure, the medium was removed, and the cells were fixed with 1% 
glutaraldehyde for 15 min and stained with 0.5% crystal violet.  Cell growth 
was measured using a crystal violet assay as previously described. Each assay 
was performed in duplicate and the experiments were repeated once. 
 
2.6.1.3. Combination drug treatment: Flow cytometry 
Bladder cancer cells UM-UC-6 were treated with varying concentrations of 
3MA (0, 1.25 and 2.5 mM), alone or before RAD001 (0 and 100 nM) and 
incubated as described before. UM-UC-9 was also were treated with varying 
concentrations of 3MA (0, 1.25 and 2.5 mM), alone or before RAD001 (0 and 
100 nM). PI FACS and PI exclusion assays were performed 24 hours after 






2.6.2. Chemotherapeutic and other drugs treatment 
2.6.2.1. Reagents and drug preparation  
Cisplatin and Gemcitabine were obtained from Sigma (St Louis, MO, USA). 
Gemcitabine was dissolved with PBS and aliquoted in concentrations of 10 
mM. The in vitro experiments with Cisplatin were performed in reduced light 
conditions, due to light sensitivity. Drugs were filtered through a 2 µm-pore 
filter prior to cell treatment. 
 
2.6.2.2. In vitro cell growth with drug treatment 
Bladder cancer cells (UM-UC-3, UM-UC-6, UM-UC-9, UM-UC-14, T24 and 
KU-7) were plated into six-well plates at a density of 1.25 × 104 cells/well. 
After 24 hours, the cells were treated with varying concentrations of Cisplatin 
(0.1, 1, 10, 50, and 100 µM) or Gemcitabine (0.01, 0.1, 1, 5, and 10 µM) and 
incubated at 37C in a humidified chamber with 5% of CO2. After 1 and 
2 days of exposure to either Cisplatin or the control (DMSO), the medium was 
removed, and the cells were fixed with 1% glutaraldehyde for 15 min and 
stained with 0.5% crystal violet. After 2 and 3 days of exposure to either 
Gemcitabine or the control (DMSO), the medium was removed, and the cells 
were fixed with 1% glutaraldehyde for 15 min and stained with 0.5% crystal 
violet. Cell growth was measured using a crystal violet assay as previously 
described. Each assay was performed in duplicate and the experiments were 
repeated once. 
 





Bladder cancer cells UM-UC-3, UM-UC-9 and T24 were plated into six-well 
plates at a density of 1.25 × 104 cells/well. After 24 hours, they treated with 
varying concentrations of Cisplatin (0, 1, 5, and 10 µM) in combination with 
RAD001 (0, 0.5 and 1 nM for UM-UC-3, 0, 5 and 10 nM for UM-UC-9 and 0, 
1 and 10 nM for T24 ).  Similarly, UM-UC-3 was treated with varying 
concentrations of Gemcitabine (0, 0.01, 0.1, and 1 µM) in combination with 
RAD001 (0, 0.5 and 1 nM). After 48 and 72 hours of exposure to the drugs, 
the medium was removed, and the cells were fixed with 1% glutaraldehyde for 
15 min and stained with 0.5% crystal violet. Cell growth was measured using a 
crystal violet assay as previously described. Each assay was performed in 
duplicate and the experiments were repeated once. Combinatory effect of the 
two drugs was calculated using the CompuSyn software based on Chou’s 
median-effect principle and combination index equation (Chou 2006).  
 
2.6.3. Small interfering RNA transfection 
 
UM-UC-3, UM-UC-6 and UM-UC-9 were transfected with 6μl (100nM) of 
small interfering RNA (SiRNA) targeting mTOR and control non-specific 
SiRNA (Cell Signaling, Beverly, MA, USA) in the presence of transfection 
reagent TransIT-TKO (Mirus, Madison, WI, USA) for 24 hours according to 
the  manufacturer’s instructions. Another transfection reagent was also used 
for transfection and prepared as follows: 2 μl of targeting mTOR and control 
non-specific SiRNA (Cell Signaling) was used for transfection. The cells were 
washed twice with PBS respectively, and 1ml of Eagle’s minimum essential 
medium without serum was added to the well.  Following which, the SiRNA 
was complexed with 20μg of DOTAP (Roche Diagnostics, Mannheim, 





MO). The final complex mixture was formed by adding 20mM HEPES buffer 
(Life Technologies, Inc., Rockville, MD), to make up a total volume of 162μl. 
This mixture is then allowed to stand for 10 min at room temperature before 
being added (drop by drop) to cells or tissue and incubated for 2 to 6 hours at 
37°C. Then cells were washed and replaced with 3 ml of fresh Eagle’s 
minimum essential medium (Wu, Mahendran et al. 2003). Total protein lysate 
was collected 48 hours after transfection and analyzed by Western blotting. In 
a parallel experiment, SiRNA transfected cells plated in 6-wells plates were 
dislodged with 0.25% trypsin, at 3 and 5 days for crystal violet assay as 
described above. In vitro experiments were performed in duplicates and 
repeated once. 
 
2.7. Statistical analysis 
Differences between the groups were tested by using the unpaired Student t 

















































3.1 Gene Polymorphism and Response to Bacillus Calmette-Guérin 
Therapy for Bladder Cancer 
 
We hypothesized that NRAMP1 and hGPX1 gene polymorphisms may 
influence the response to intravesical BCG immunotherapy in patients with 
NMIBC. The aim of this part of the study is to determine the predictive value 
of these gene polymorphisms for cancer recurrence and response to 
intravesical BCG immunotherapy, in high risk NMIBC patients.  
 
3.1.1. Selection of clinical trial patients 
 
All Patients who underwent TUR for NMIBC (urothelial carcinoma) and were 
at risk for recurrence or progression (CIS, T1, G2, G3, or multiple or recurrent 
Ta / G1 tumours) and had no prior intravesical therapy, were enrolled 
prospectively and randomized to receive one of three forms of intravesical 
BCG (Connaught strain, Connaught Laboratories Limited, Pasteur Métrieux 
Connaught, Canada). The 3 groups comprised standard dose (81 mg) BCG, 
1/3 dose (27 mg) BCG and 1/3 dose BCG plus 10 million units of interferon 
alpha 2b (IFNa). All patients (n=103) had given written informed consent. The 
study was also approved by the NUS institutional review board (on 8 August 
2006). 
 
3.1.2. Inclusion Criteria 
 Patients’ recruitment age criteria were from 18 to 99 years. Prior to 
recruitment, all patients must have completely resected, histologically-proven 
grade 2 or 3 transitional cell carcinoma of the urinary bladder, stage Ta or T1, 





have previously received and completed intravesical BCG therapy with or 
without Interferon (IFN) alpha.  
 
3.1.3. Exclusion Criteria 
The exclusion criteria were applied as follows: patients who were unable to 
give consent, patients who had not completed intravesical BCG therapy for 
any reason, and patients who had defaulted from follow-up protocol after BCG 
therapy. 
 
3.1.4. Study Design 
The regime comprised an induction course of 6 weekly instillations, a 6 week 
break and a final booster course of 3 once-a-week instillations. The patients 
were followed up by 3 monthly cystoscopy and urinary cytology for three 
years and 6-monthly thereafter. Bladder biopsy & urinary cytology were 
performed when indicated. Vesical recurrence and tumour stage progression 
were defined as the occurrence of any new focus of NMIBC and muscle 
invasion (>stage T2) respectively. Recurrence, stage progression or cancer-
specific deaths were end points for this analysis. 
 
3.1.5. Control Subjects 
Eighty five healthy normal young volunteers (comprising university 
undergraduates and laboratory staff in their 20’s who had undergone health 
screening at enrolment or employment respectively) were also recruited as 






3.1.6. Collection and storage of samples 
Peripheral blood samples were obtained from all patients (3mls) and control 
subjects (finger prick samples), and stored at -80C. 
 
3.1.7. Patient characteristics 
The patients comprised 83.8% Chinese, 8.1% Malays, 6.1% Indians and 2% 
Caucasians. 79.8% of patients were males and 20.2% were females. Based on 
the factors used in the EORTC bladder cancer risk tables and scoring system, 
69.7% of our patients were considered high risk for recurrence or progression, 
while 30.3% were of intermediate risk (Table 3.1.1) (Sylvester, van der 
Meijden et al. 2006). Patient, disease and genotypic characteristics of 99 
evaluable patients, were similar among treatment groups (Table 3.1.1). Patient 
and tumour characteristics were similar when stratified by genotype (Table 
3.1.2).  
 
3.1.8. Treatment outcome 
Patients were followed up for a median of 60 months. There were 22 non 
cancer-specific deaths at a median of 36 months (81 mg BCG group:11/50, 
27mg BCG group:5/19, BCG-IFNa group:6/30) and 7 cancer-specific deaths 
at a median of 60 months (81 mg BCG group:6/50, BCG-IFNa group:1/30). 
Eleven patients progressed to muscle invasive disease, at a median of 39 
months after therapy (81 mg BCG group: 7/50, 27mg BCG group:2/19, BCG-
IFNa group:2/30). The clinical outcome (recurrence-free, progression-free and 
cancer-specific survival) of patients who received standard dose (81 mg) BCG 





the two groups for analysis. The analysis was also not stratified by gender, as 




























Table 3.1.1. Patient and tumour characteristics, and treatment outcomes, 
stratified by treatment groups. 
 





















0.667 63.9  
(28-82) 
Male (%) 42 (84) 16 (84.2) 21 (70) 0.278 79 (79.8) 
Stage (%)      




Ta 8 (16) 4 (21) 9 (30) 21 (21.2) 
T1 26 (52) 9 (47.4) 13 (43.3) 48 (48.5) 
Grade (1973 WHO) (%)      




G2 21 (42) 13 (68.4) 12 (40) 46 (46.5) 
G3 18 (36) 4 (21.1) 11 (36.7) 33 (33.3) 
Number of tumours      




2-7 17 (34) 9 (47.4) 15 (50) 41 (41.4) 
> 8 7 (14) 2 (10.5) 4 (13.3) 13 (13.1) 
unknown 1 (2) 0 0  1 (1.0) 
Tumour size      
< 3 cm 47 (94) 16 (84.2) 23 (76.7)  
0.079 
86 (86.9) 
> 3 cm 3 (6) 3 (15.7) 7 (23.3) 13 (13.1) 
unknown 0 0 0  0 
Prior recurrence rate      




< 1 recurrence/year 6 (12) 1 (5.3) 8 (26.7) 15 (15.2) 
> 1 recurrence/year 18 (36) 5 (26.3) 10 (33.3) 33 (33.3) 
unknown 0 2 (10.5) 0  2 (2.0) 
Genotype      
(GT)n  (%)      






1:2 11 (22) 1 (5.26) 8 (26.7) 20 (20.2) 
1:3 1 (2) 2 (10.52) 1 (3.3) 4 (4) 
2:2 1 (2) 0 1 (3.3) 2 (2) 
2:3 0 1 (5.26) 1 (3.3) 2 (2) 
3:3 0 1 (5.26) 0 1 (1) 
D543N (%)      




G:A 14 (28) 8 (42.1) 10 (33.3) 32 (32.3) 
G:G 36 (72) 11 (57.9) 20 (66.7) 67 (67.7) 
hGPX1 (%)      




CT 3 (6) 2 (10.5) 1 (3.3) 6 (6.1) 
TT 0 0 0 0 
Smoking History (%)      
Positive 27 (54) 10 (52.6) 12 (40) 0.414 49 (49.5) 
BCG vaccination (%)      






Table 3.1.2. Characteristics of all BCG treated patients stratified by different genotypes.


































(years) 63.9 64.8 62.8 48.5 71.5 61 0.417 63.8 63.9 0.98 63.9 63.7 0.965 
Ethnicity (%)
Chinese 







0.435 Malays (n=8) 8.6 5 0 50 0 0 9.4 7.5 8.6 0 Indians (n=6) 5.7 10 0 0 0 0 3.1 7.5 5.4 16.7 
Caucasians 
(n=2) 1.4 5 0 0 0 0 3.1 1.5 2.2 0 
Stage (%)            





0.337 Ta 45.7 60 25 100 50 0 37.5 53.7 50 48.4 
T1 22.9 15 50 0 0 0 21.9 20.9 0 22.6 
Grade (%)              





0.667 G2 45.7 45 50 50 50 100 43.8 47.8 33.3 47.3 





3.1.9. Gene polymorphisms compared to population 
In accordance to the Hardy–Weinberg equilibrium, which states that both 
allele and genotype frequencies in a population should remain constant, we 
compared the genotypes frequencies between patients and a sample of the 
normal population. The distribution of the various polymorphisms of D543N 
was similar between NMIBC patients (n=99, A:A - 0%, A:G – 32%, G:G – 
68%) and normal volunteers in our population (n=85, A:A - 2%, A:G – 27%, 
G:G – 71%). Patients (83.8%) and controls (85.9%) were predominantly 
Chinese. The hGPX1 leu allele (CT genotype) varies between ethnic groups. 
Its frequency in our study was 0.061, which was similar (0.05) to that in a 
previous Asian study (Ichimura, Habuchi et al. 2004). 
 
3.1.10. Univariate Analysis 
Univariate analysis of patient’s treatment outcome, stratified according to 
genotypes and BCG therapy or overall is detailed in Table 3.1.3. The 
NRAMP1 D534N G:G genotype had a higher recurrence and shorter 
recurrence-free survival (p=0.033) in BCG only treated patients (Table 3.1.3 
and Figure 3.1.1A). Overall, the D534N G:G genotype patients had decreased 
time to cancer-specific death (p=0.036) (Table 3.1.3 and Figure 3.1.1B). The 
NRAMP1 (GT)n 2:3 genotype had shorter progression-free survival in BCG 
only treated patients (p=0.002) and overall (p<0.001) (Table 3.1.3). The allele 
3 (GT)n gene polymorphism correlated with shorter recurrence-free (p=0.024) 
and progression-free survival (p=0.005) in patients treated with BCG-IFNa, in 
the univariate analysis. However, the sample sizes for patients with (GT)n 2:3, 





with a shorter recurrence-free survival (p=0.018) in patients treated with BCG-
IFNa (Table 3.1.3). Overall, patients with hGPX1 CT genotype had an 
increased bladder cancer recurrence and decreased recurrence time (p=0.03) 


























Table 3.1.3. Univariate analysis* of patient response to BCG immunotherapy 
stratified genotypes, and treatment arm. 
 
 Genotype\ Median 
time to: (months) 





















1 CC (n=93) 97.1 (n=27) 120.3 (n=9) 125.3 (n=6) 106.8 (n=22) 
CT (n=6) 49.5 (n=4) 90 (n=2) 109.5 (n=1) 0 
P value 0.03 0.131 0.477 0.223 
HR (95% CI) 3.0 (1.04-8.6) 3.1 (0.7-14) 2.1 (0.3-18) 0.1 (0.01-94) 
      




 G:A (n=32) 100 (n=7) 127.3 (n=2) 0 108.9 (n=8) 
G:G (n=67) 87.6 (n=24) 114.6 (n=9) 118.9 (n=7) 108.9 (n=14) 
P value 0.102 0.233 0.036 0.980 
HR (95% CI) 2.0 (0.8-4.6) 2.5 (0.5-11) 44 (1.01-300) 1.1 (0.4-2.4) 




1:1 (n=70) 87.4 (n=22) 111.8 (n=8) 122.9 (n=6) 111.6 (n=14) 
1:2 (n=20) 96.9 (n=6) 128.6 (n=1) 128.3 (n=1) 102.0 (n=5) 
1:3 (n=4) 66.7 (n=2) 115.2 (n=1) 0 0 
2:2 (n=2) 0 0 0 0 
2:3 (n=2) 21(n=1) 21 (n=1) 0 42 (n=2) 
3:3 (n=1) 0 0 0 93 (n=1) 
P value 0.485 <0.001 0.960 0.027 








   
hG
PX
1 CC (n=29) 95.5 (n=7) 118.5 (n=1) 0 101.4 (n=6) 
CT (n=1) 6 (n=1) 27 (n=1) 60 (n=1) 0 
P value 0.018 1.0 1.0 0.611 
HR (95% CI) 28 (1.7-400) 1.0(0.01-500) 1.0 (0.01-400) 0.1 (0.01-100) 
      




 G:A (n=10) 78.6 (n=3) 99.3 (n=1) 0 97.5 (n=1) 
G:G (n=20) 95.3 (n=5) 117.3 (n=1) 117.3 (n=1) 98.2 (n=5) 
P value 0.686 0.679 0.460 0.406 
HR (95% CI) 0.7 (0.2-3.1) 0.6 (0.1-9.0) 40.0 (0.1-100) 2.4 (0.3-20) 




1:1 (n=19) 99.3 (n=4) 116.6 (n=1) 117.3 (n=1) 111.8 (n=2) 
1:2 (n=8) 70.5 (n=3) 0 0 74 (n=3) 
1:3 (n=1) 21 (n=1) 56 (n=1) 0 0 
2:2 (n=1) 0 0 0 0 
2:3 (n=1) 0 0 0 3 (n=1) 
3:3 (n=0) - - - - 
P value 0.228 0.384 1.0 < 0.001 







1 CC (n=64) 94.2 (n=20) 116.9 (n=8) 122.2 (n=6) 105.9 (n=16) 
CT (n=5) 58.2 (n=3) 102.6 (n=1) 0 0 
P value 0.207 0.800 0.448 0.253 
HR (95% CI) 2.1(0.6-7.2) 1.3 (0.2-10.6) 0.04 (0.01-200) 0.04 (0.01-168) 
      




 G:A (n=22) 104.6 (n=4) 129.6 (n=1) 0 105 (n=7) 
G:G (n=47) 80.2 (n=19) 110.6 (n=8) 117.0 (n=6) 110.4 (n=9) 
P value 0.033 0.131 0.057 0.585 
HR (95% CI) 3.0 (1.03-8.9) 4.3 (0.5-35) 43.0 (0.1-400) 0.8 (0.3-2.0) 




1:1 (n=51) 82.9 (n=18) 109.6 (n=7) 121.7 (n=5) 108.4 (n=12) 
1:2 (n=12) 99.6 (n=3) 123 (n=1) 123.2 (n=1) 108.9 (n=2) 
1:3 (n=3) 82.0 (1) 0 0 0 
2:2 (n=1) 0 0 0 0 
2:3 (n=1) 21 (n=1) 21 (n=1) 0 81 (n=1) 
3:3 (n=1) 0 0 0 93 (n=1) 
P value 0.677 0.002 0.966 0.547 







                      
Fig. 3.1.1. Kaplan-Meier actuarial disease related survival, comparing (A) 
recurrence-free survival of the G:A and G:G genotypes of D543N 
polymorphism in the NRAMP1 gene for patients who received BCG only 
therapy, (B) cancer-specific survival of the G:A and G:G genotypes of D543N 







3.1.11. Combination of prognostic genotypes 
No patient had all 3 poor prognostic genotypes (NRAMP1 D534N G:G and 
(GT)n allele 3 and hGPX1 CT genotype). The combination of D534N G:G 
genotype and hGPX1 CT genotype was associated with the poorest outcome, 
having increased recurrence rates (p=0.016); decreased recurrence time 
(p=0.003); increased progression rates (p=0.035) and a trend towards 
decreased time to progression (p=0.075) after BCG therapy, compared to 
patients with other genotypic combinations (Table 3.1.4). 
 
 
Table 3.1.4. Patient’s treatment outcome, stratified by the combination of 
NRAMP1 and hGPX1 genotypes with the poorest outcomes (patients who 
have both D543N G:G + hGPX1 CT, compared to other genotypic 
combinations). Data on recurrence and progression for patients with D543N 














































       
Genotypes D543N 



















































3.1.12. Multiple logistic and Cox regression analyses 
Cox regression analysis of all patients (considering age, gender, ethnicity, 
tumour stage and grade, smoking history, BCG vaccination status, treatment 
groups and genotypes) showed that NRAMP1 D534N G:G and (GT)n allele 3 
were associated with decreased recurrence time (p=0.014, HR 4.57, 95%CI 
1.367–15.272 and p=0.03, HR 24.789, 95%CI 3.074–199.883 respectively). 
The absence of prior BCG vaccination predicted for decreased overall survival 
(p=0.035, HR 0.314, 95%CI 0.107–0.92). Multiple logistic regression analysis 
considering the same factors showed that patients with CIS (p=0.031, HR 
7.576, 95%CI 1.201–47.776), NRAMP1 D543N G:G (p=0.035, HR 4.709, 
95%CI  1.117–19.857) and (GT)n allele 3  (p=0.022, HR 48.686, 95%CI 
1.736–1365.659) genotypes were more likely to recur after BCG 
immunotherapy. Increased patient age predicted for decreased recurrence time 
(p=0.038, HR 1.06, 95% CI 1.0-1.11) and decreased overall survival 
(p<0.0001, HR 1.178, 95% CI 1.085–1.278) in the cox regression analysis, 
and was associated with increased risk of overall death (p=0.002, HR 1.145, 
95%CI 1.051–1.247) in the multiple logistic regression analysis. All other 
factors were not significantly associated with outcomes in both analyses. The 
















Fig.3.1.2. The relative weight of clinical, pathological and genetic predictors 
for (A). recurrence, using multiple logistic regression analysis, and (B). time to 
recurrence, using cox regression analysis, in NMIBC patients who underwent 













We found that polymorphisms of the NRAMP1 and hGPX1 genes may be 
associated with recurrence of bladder cancer after BCG immunotherapy. A 
patient having a combination of the poor risk genotypes may be at risk of 
disease progression. Patients with these gene polymorphisms are not likely to 
respond to BCG therapy. Despite intravesical BCG therapy being the current 
gold standard therapy for non-muscle invasive bladder cancer, it still has a 
relatively high failure rate. Therefore our findings suggest a need to search for 





















3.2. mTOR Target therapy for bladder cancer cells 
As there is very limited data on the importance of the PI3K-AKT-mTOR 
pathway in bladder cancer and its therapeutic benefit, we sought to understand 
the importance of mTOR in bladder cancer cell by inhibiting its function. 
 
3.2.1. Growth-inhibitory effects of RAD001 in vitro 
The bladder cancer cell lines UM-UC-3, UM-UC-6, UM-UC-9, and UM-UC-
14 were initially chosen due to the known varied p53, pAKT and PTEN status 
of the cell lines, in order to better understand the effects of RAD001 on the 
PI3K-AKT-mTOR pathway (see Table 2.2 in methods section). The cell lines 
were treated with increasing doses of RAD001 (0.1 nM to 100 nM) and 
incubated for up to 6 days. In all four cell lines RAD001 inhibited the growth 
of bladder cancer cells tested in a dose-dependent manner, with a partial loss 
of response seen 4 days after initial treatment (Fig. 3.2.1A). The UM-UC-14 
cell line was the most sensitive to RAD001, with an IC50 of 0.1 nM, the UM-
UC-3 and UM-UC-6 cell lines had moderate sensitivities, with IC50s of 0.5 
nM, and the UM-UC-9 cell line was the least sensitive, with an IC50 of 10 nM. 
Retreatment of cells with RAD001 (at a dose corresponding to each cell line’s 
IC50) 3 days after the initial therapy augmented the growth inhibition in all 
four bladder cancer cell lines (Fig. 3.2.1B). The timing of redosing at day 3 
was based on the observation that there was loss of response to RAD001 in all 
four cell lines from day 4 of incubation (Fig. 3.2.1A). The transient effect of a 
single dose of RAD001 is likely related to its half-life of 60 hours (Laplanche, 






Fig 3.2.1A. The inhibitory effects of RAD001 on bladder cancer cell growth determined by crystal violet assays. UM-UC-3, UM-UC-6, UM-






Fig 3.2.1B. The inhibitory effects of RAD001 on bladder cancer cell growth 
determined by crystal violet assays. Cells were treated with RAD001 initially 
at day 0 and then retreated at day 3 with a dose equivalent to the IC50 for each 
cell line and incubated for 5 days. 
 
 
3.2.2. Effect of RAD001 on cell proliferation in vitro 
The [3H]Thymidine incorporation assays showed that there were dose 
dependent decrease in the number of bladder cancer cells proliferating when 
treated with RAD001 (Fig. 3.2.2). This was consistent with the growth 
inhibitory effects of RAD001 on bladder cancer cells seen in the crystal violet 






Fig. 3.2.2. The inhibitory effects of RAD001 on bladder cancer cell proliferation determined by [3H]Thymidine incorporation assays. UM-UC-3, 





3.2.3. Effect of RAD001 on cell cycle 
All four cell lines were treated once with increasing doses of RAD001 (0.1 
nM, 0.5 nM, 10 nM, and 100 nM), and cell cycle analysis was performed at 
various time points (24, 48, and 72 hours). We saw no specific growth phase 
arrest with a single treatment of RAD001 in any of the four cell lines tested 
(Fig 3.2.3). When we re-treated UM-UC-6 and UM-UC-9 cell lines with 
RAD001, 3 days after the initial dose, only the UM-UC-6 cells were arrested 
in the G0/G1 phase (p = 0.01), with corresponding decrease in S phase (p = 
0.02) (Fig 3.2.3). Even with prolonged re-treatment every 3 days up to 10 
days, there was no specific growth phase arrest seen in UM-UC-9 cells (Fig. 
3.2.4). There was no difference in the percentage of cells in the sub-G1 phase 
between controls and RAD001-treated cells, suggesting the absence of 
apoptosis, both in the single treatment or re-treatement experiments (Fig 3.2.3 









Fig. 3.2.3. Flow cytometric analysis of bladder cancer cell lines. (A) cell-cycle analysis was done at 48 hours for control- and RAD001-treated 
(0.5 nM) UMUC- 6 cells, control- and RAD001-treated (10 nM) UM-UC-9 cells, (B) UM-UC-6 cells treated with RAD001 (0.5 nM) every 3 
days (*p = 0.01, #p = 0.02), and UM-UC-9 cells treated with RAD001 (10 nM) every 3 days (n.s.). Bar charts comparing the differences in the 








Fig. 3.2.4. Flow cytometric analysis of UM-UC-9 cells treated with RAD001 
(10 nM) every 3 days. Bar charts comparing the differences in the percentage 
of sub-G1/G1/S/G2-phase cells between controls and RAD001 treated cells 
are shown. No specific growth phase arrest was seen in UM-UC-9 cells. 
 
 
3.2.4. Effect of RAD001 on apoptosis 
We did not see any evidence of early apoptosis in any of the four cell lines 
tested by Annexin V assays, which were performed 12 and 24 hours after a 
single treatment of cells with RAD001, even at doses as high as 100 nM 
(Table 3.2.1). We corroborated these findings with PI exclusion assays 24 and 
48 hours after RAD001 treatment, which suggest that RAD001 induced non-
apoptotic cell death at the IC50 doses in all of the bladder cancer cell lines 
























Table 3.2.1. Annexin V assays, which were performed 12 and 24 hours after a single treatment of cells with RAD001. Annexin V-FITC signals 
are expressed as mean fluorescence intensity (MFI). No definite evidence of early apoptosis (Annexin V positive and PI negative area; Annexin 

























   
MFI of Annexin V+ / PI- RAD001 p-value 
UM-UC-3 Control 0.5nM 10nM 100nM  
12 hours 1.39 1.62 1.75 1.32 ns 
UM-UC-6 Control 0.5nM 10nM 100nM  
24 hours 5.39 4.96 5.26 5.77 ns 
UM-UC-9 Control 0.5nM 10nM 100nM  
12 hours 3.66 3.96 3.56 4.09 ns 
24 hours 4.39 - 3.04 2.47 ns 
UM-UC-14 Control 0.1nM 10nM 100nM  
12 hours 3.09 2.99 2.05 2.53 ns 





Table 3.2.2. PI exclusion assays were conducted 24 and 48 hours, after UM-UC-3, UM-UC-6, UM-UC-14 and UM-UC-9 cells were treated with 
RAD001. Percentages of cells undergoing non-apoptotic cell death are shown (left panel). Examples of flow cytometric profiles of cells 







Percentage of cells undergoing 
non-apoptotic cell death (%) 
RAD001 
UM-UC-3 Control 0.5nM 10nM 100nM 
24 hours 
0.78 2.94 9.51 3.32 
UM-UC-6 Control 0.5nM 10nM 100nM 
24 hours 
8.05 15.3 16.7 15.5 
UM-UC-14 Control 0.1nM 10nM 100nM 
 24 hours 
8.31 12.2 18.2 26.3 
UM-UC-9 Control 0.5nM 10nM 100nM 
24 hours 
14.6 16.2 15.3 17.3 
48 hours 





3.2.5. Effect of RAD001 on protein synthesis 
Using a radioactively labeled amino acid (leucine), we demonstrated that 
RAD001 inhibited protein synthesis in all four bladder cancer cell lines (Fig 
3.2.5, data not shown for cell lines UM-UC-3 and UM-UC-14).  
 
Fig 3.2.5. Protein synthesis assay using radioactively labeled amino acid 
(leucine) was performed 2 and 12 hours after treatment of UM-UC-6 cells and 
UM-UC-9 cells with RAD001. Cells treated with cycloheximide were used as 







3.2.6. Downstream effects of mTOR blockade by RAD001 
To investigate the effects of RAD001 treatment on mTOR signaling, we used 
western blotting to analyze the levels of the phosphorylated forms of mTOR, 
p70S6K, 4E-BP-1 and non-phosphorylated forms of mTOR and p70S6K, after 
a single 24-h exposure of UM-UC-3, UM-UC-6, UM-UC-9, and UM-UC-14 
cells to various doses of RAD001. In all four cell lines, the levels of the 
phosphorylated forms of mTOR, p70S6K, and 4E-BP-1 were reduced with 
increasing doses of RAD001, but the effects of RAD001 on the non-
phosphorylated form of mTOR protein levels in each cell line were different, 
with only UM-UC-3 and UM-UC-6 having a slight decrease in mTOR levels 
with increasing RAD001 dose (Fig. 3.2.6). No downstream effect of RAD001 
was seen in the non-phosphorylated form of p70S6K in all 4 cell lines (Fig 
3.2.6). Overall, the effects of RAD001 on the levels of these proteins in the 
mTOR signaling pathway did not correlate with the relative sensitivity of each 



















3.3. Effects of RAD001 in vivo 
3.3.1. Animal work 
Having shown efficacy of mTOR inhibition in vitro, we sought to further 
investigate the efficacy of mTOR inhibition in an animal model, so as to 
provide further evidence of its viability as a possible therapeutic option for 
bladder cancer. UM-UC-3, UM-UC-6, and UM-UC-9 cells were implanted 
subcutaneously into nude mice, and when the xenograft tumours reached 5 
mm in diameter, the mice were treated with RAD001 by oral gavage twice per 
week for 1 month. RAD001 significantly inhibited the growth of tumours 







Fig. 3.3.1. In vivo growth inhibitory effect of prolonged treatment of 
subcutaneous tumour–bearing nude mice. The graphs show tumour size with 
time after RAD001 or placebo treatment in mice with UM-UC-3-, UMUC-6-, 





3.3.2. Immunohistochemistry of tumour tissue 
Immunohistochemical analysis of tumour tissue samples demonstrated 
reduced expression of phosphorylated p70S6K in the RAD001-treated UM-
UC-3– and UM-UC-6–derived tumours compared with control-treated 
tumours, while the expression of phosphorylated p70S6K in RAD001-treated 
UM-UC-9–derived tumours was unchanged (Table 3.3.1 and Fig. 3.3.2). There 
was no difference in the expression level of phosphorylated mTOR between 
the RAD001-treated and control-treated tumours. For the UM-UC-3– and 
UM-UC-9–derived tumours, phosphorylated AKT expression was reduced in 
the RAD001-treated compared with control-treated tumours, but the 
phosphorylated AKT levels were unchanged between the RAD001-treated and 
control-treated UM-UC-6–derived tumours. Positive and negative controls are 
shown in Fig. 3.3.3. The vascular density in the tumours was measured by 
counting the number of blood vessels that expressed CD31. RAD001 
treatment did not affect the vascular density of UM-UC-6–derived tumours (p 
= 0.5503; Table 3.3.1 and Fig. 3.3.2). However, RAD001 treatment modestly 
reduced the vascular density of the UM-UC-3–derived tumours (p = 0.0597) 
and significantly reduced the vascular density of the UM-UC-9–derived 
tumours (p = 0.036; Table 3.3.1 and Fig. 3.3.2). Expression levels of VEGF 
were similar in the RAD001- and control-treated tumours derived from all 
three cell lines (Table 3.3.1), suggesting that the changes in vascular density 







Fig. 3.3.2. Immunohistochemical staining of representative tumour tissue sections harvested after prolonged treatment with either a placebo or 






Fig. 3.3.3. Separate immunohistochemical staining of representative UM-UC-3, UM-UC-6 and UM-UC-9 implanted tumour tissue sections with 





Table 3.3.1. Summary of the scoring results of immunohistochemical analysis 
for phospho-mTOR, phospho-p70S6K, phospho-AKT, CD31, and VEGF 
expression in UM-UC-3, UM-UC-6, and UM-UC-9 tumours from mice treated 
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3.4. Autophagy, oxidative stress and membrane effects of mTOR therapy 
In view of our previous results showing the presence of non-apoptotic death in 
bladder cancer cells following mTOR therapy, we aimed to determine if 
mTOR inhibition would result in autophagy, oxidative stress response and 
other membrane effects in bladder cancer cells. This was also performed in the 
effort to search for other methods of enhancing the effect of mTOR therapy on 
bladder cancer cells. 
 
3.4.1. Demonstration of accumulation of autophagic markers 
3.4.1.1. Transmission Electron Microscopy (TEM) 
We performed TEM on UM-UC-6 and UM-UC-9 cells after being treated with 
control DMSO or RAD001 at 100 nM for 12 hours. In UM-UC-6 cell line, 
frequent autophagosomes were observed in the cytoplasm of RAD001 treated 
cells but not in the controls (Fig 3.4.1 and 3.4.2). No autophagosomes were 
seen the cytoplasm of RAD001 treated UM-UC-9 cells, but instead, dilated 
mitochondria were seen (Fig.3.4.1 and 3.4.3). The results of the TEM are 
summarized in Table 3.4.1. 
 
 
Table 3.4.1. Summary of findings on TEM. 
 
 Autophagosomes Mitochondrial enlargement / 
distention 
Cell Lines Control RAD001 
(100nm) at 12 
hrs 
Control RAD001 
(100nm) at 12 
hrs 
UM-UC-6 0 + 0 0 







Fig. 3.4.1. Electron Micrographs (Magnification x 4000) of UM-UC-6 and 
UM-UC-9 cells after being treated with control DMSO or RAD001 at 100 nM. 














Fig. 3.4.2. Electron Micrographs (Magnification x 20,000) of UM-UC-6 cell 






Fig. 3.4.3. Electron Micrographs (Magnification x 20,000) of UM-UC-9 cell 








Microtubule-associated protein 1A/1B-light chain 3 (LC3) is an ubiquitin-like 
soluble protein with a molecular mass of ∼17kDa that is distributed 
ubiquitously in mammalian tissues and cultured cells (Tanida, Ueno et al. 
2008). During autophagy, autophagosomes engulf cytoplasmic components, 
which include cytosolic proteins and organelles. Concomitantly, a cytosolic 
non-lipidated form of LC3 (LC3-I) is conjugated to phosphatidylethanolamine 
to form the lipidated LC3-phosphatidylethanolamine conjugate (LC3-II), 
which is then recruited to autophagosomal membranes (Tanida, Ueno et al. 
2008). When autophagosomes fuse with lysosomes to form autolysosomes, the 
lysosomal hydrolases degrade the components within the autophagosomes. 
During that time, LC3-II in the autolysosomal lumen is also degraded. The 
lysosomal turnover of the LC3-II reflects autophagic activity, and currently, 
detecting LC3 has become a reliable method for monitoring autophagy and 
autophagy-related processes, including autophagic cell death (Tanida, Ueno et 
al. 2008). 
 
UM-UC-6 and Um-UC-9 cells were transfected with the plasmid containing 
GFP-LC3. The cells were then treated with increasing doses of RAD001 (0.5 
and 100 nM) for in full culture media. GPF fluorescence was viewed at 24, 48, 
72 hours after treatment and after repeat treatment at 4 days, using 
fluorescence microscopy to identify GFP-LC3 puntuation / aggregations in the 
cells.  It was found that RAD001 treated UM-UC-6 had more punctae within 
cells compared to control DMSO treated cells (p=0.0244) (Fig. 3.4.4. A and B, 





of increased punctuation / aggregation was seen in UM-UC-9 cells even at a 
dose of 100 M of RAD001 (Fig. 3.4.5. A and B). When we pretreated UM-
UC-6 cells with autophagic inhibitors 3MA or LY294002, followed by 
RAD001 treatment, no significant presence of punctuation / aggregation was 
seen compared to controls and 3MA or LY294002 alone (Fig. 3.4.4. A and B). 
This suggested that RAD001 induces the process of autophagy in UM-UC-6 



























Fig. 3.4.4. (A). Flourescence microscopy images (x250 magnification) of 
GFP-LC3 transfected UM-UC-6 cells treated with control DMSO, RAD001 
100nM, 3MA 2.5 mM + RAD001 100 nM and LY294002 20 µM + RAD001 
100 nM. (B). Bar chart showing the GFP-LC3 puncta / cell counts 










Fig. 3.4.5. (A). Flourescence microscopy images (x250) of GFP-LC3 
transected UM-UC-9 cells treated with control DMSO or RAD001 100nM. 
(B). Bar chart showing the GFP-LC3 puncta / cell counts corresponding to the 
treatment groups in (n.s.) (A). 
 
 
3.4.2. Oxidative stress and membrane effects of mTOR therapy 
Activation of the PI3K-mTOR pathway is known to cause elevation of ROS 
(Kim, Chu et al. 2005). Also in view of our TEM findings of enlarged 





RAD001 on cellular ROS and mitochondrial membrane potential changes in 
bladder cancer cells. 
 
3.4.2.1. Effects of mTOR inhibition on intracellular Reactive Oxygen 
Species (ROS) 
To determine the effect of RAD001 on cellular oxidative stress, UM-UC-6 and 
UM-UC-9 cells were treated with RAD001 or control DMSO for 6 and 12 
hours, with hydrogen peroxide as positive controls. The cells were then stained 
with CM-H2DCFDA and fluorescence intensity was read by flow cytometry. 
The fluorescence intensity counts in UM-UC-6 treated with RAD001 were 
significantly lower compared to untreated cells at 6 hours (p=0.0013) but not 
at 12 hours after RAD001 treatment, while there was no difference seen 











Fig. 3.4.6. Fluorescence intensity counts of the ROS assay with CM-
H2DCFDA, relative to control are shown. UM-UC-6 and UM-UC-9 cells were 
treated with control DMSO or RAD001, and incubated for 6 and 12 hours. 
Media containing DMSO and 3 μM hydrogen peroxide (data not shown) was 





3.4.2.2. Effects of mTOR inhibition on mitochondrial membrane potential 
(MMP) changes 
To determine the effect of RAD001 on MMP changes, UM-UC-6 and UM-
UC-9 cells were treated with RAD001 or control DMSO for 12 and 24 hours, 
with hydrogen peroxide as positive controls. The cells were then stained with 
Rhodamine-123and fluorescence intensity was read by flow cytometry. There 
was no difference seen between fluorescence intensity counts in RAD001 









Fig. 3.4.7. Fluorescence intensity counts of the MMP assay with Rhodamine-
123, relative to control are shown. UM-UC-6 and UM-UC-9 cells were treated 
with control DMSO or RAD001, and incubated for 12 and 24 hours (n.s.). 
Media containing DMSO and 3 μM hydrogen peroxide (H202) was used as 
negative and positive controls respectively. 
 
3.5 Enhancing mTOR therapy 
3.5.1. Autophagic inhibitor Treatment 
It is currently unknown whether autophagy contributes to the anti-tumour 
effect of mTOR inhibition or to drug resistance. Autophagic inhibitors such as 
Chloroquine and 3MA have been studied for possible roles as anti-tumour 
drugs (Kimura, Takabatake et al. 2013). We aimed to determine if autophagic 
inhibitors could enhance the effect of RAD001 in bladder cancer cells. 
 





UM-UC-6 and UM-UC-9 cells were treated with varying concentrations of 
Chloroquine (0, 2.5, 5, 10, 25 and 50 µM) and 3MA (0, 2.5, 5 and 10 mM) to 
determine their least toxic dose to the cells (data not shown). UM-UC-6 and 
UM-UC-9 cells were then pre-treated with Chloroquine or 3MA and then in 
combination with RAD001 (at IC50 and high dose), and incubated up to 4 
days. When a low dose of 3MA was combined with RAD001, there was more 
cell death in UM-UC-6 cells compared to 3MA or RAD001 alone (p < 0.01), 
but no such difference was seen in UM-UC-9 cells (Fig. 3.5.1). When 
Chloroquine was combined with RAD001, there was slightly more cell death 
in UM-UC-6 cells the group containing Chloroquine plus RAD001 0.5nM, 
compared to Chloroquine or RAD0010.5 nM alone, but no difference was seen 
in the group containing Chloroquine plus a higher dose of RAD001 (100nM), 
and for UM-UC-9 cells, there was also no difference seen between treatment 









Fig. 3.5.1. The inhibitory effects of 3MA + RAD001 on UM-UC-6 and UM-UC-9 cell growth determined by crystal violet assays. Cells were 
treated with Control DMSO, RAD001, 3MA or 3MA + RAD001 initially at day 0 and incubated for up to 4 days [*p < 0.01 comparing 3MA + 







3.5.3. Combining autophagic inhibition and mTOR inhibition: Flow 
cytometry 
We attempted to verify the findings seen in crystal violet assays by performing 
flow cytometry to determine if there was difference in the number of cell 
deaths, as well as the type of cell death seen in the combination group (3MA + 
RAD001) as compared to individual treatments. UM-UC-6 and UM-UC-9 
cells were treated with 3MA either 1.25 mM or 2.5 mM + RAD001 100 nM, 
as previously described and incubated for 24 hours. PI FACS and PI exclusion 
assays were then performed. When 2.5 mM of 3MA was combined with 
RAD001, there was more total cell death in the UM-UC-6 cells when 
compared to 3MA or RAD001 alone (Fig. 3.5.2). The percentage of apoptosis 
in UM-UC-6 cells was increased in both the 3MA (2.5 mM) group and the 
3MA + RAD001 group compared to controls or RAD001 alone (Fig. 3.5.2). 
The percentage increase was more marked in the 3MA + RAD001 group than 
the 3MA (2.5 mM) alone group. No such differences were seen when cells 
were treated with a lower dose of 3MA (1.25 mM) or its combination with 
RAD001 (data not shown). There were no differences in cell death or percent 
apoptosis seen across treatment groups in UM-UC-9 cells (Fig. 3.5.2). This 
result corroborates our findings seen in the crystal violet assays. It may also 
suggest that autophagic inhibition by 3MA may result in increased death, 
possibly through apoptotic pathways. Apoptosis after combination therapy 
appeared to be slightly increased compared to 3MA alone, although 
significance was not reached. The combination treatment may also accelerate 
time to death from mTOR therapy, as significant cell death from mTOR 





These would only occur in cells which can undergo autophagy with RAD001 
and not in those cells which do not. However, more studies need to be 




Fig. 3.5.2. PI FACS and PI exclusion assays performed using flow cytometry. 
UM-UC-6 and UM-UC-9 cells were treated with Control DMSO, RAD001, 
3MA (2.5 mM) or 3MA (2.5 mM) + RAD001 (100 nM) initially and incubated 
for 24 hours. [*p < 0.01 comparing total cell death from 3MA + RAD001 100 
nM with 3MA or RAD001 (100 nM), and #p < 0.05 comparing percentage 
apoptosis with 3MA + RAD001 100 nM with RAD001 100 nM].  
 
3.6. Enhancing chemotherapy with mTOR inhibition 
Currently chemotherapy is not only being used in advanced muscle invasive 
bladder cancer but also in the form of intravesical therapy for NMIBC. 
Cisplatin and Gemcitabine have been given through the systemic or 





vary between patients. Cisplatin and Gentamicine sensitivity have been 
suggested to be partially dependent on p53 status in bladder and other cancer, 
with decreased response associated with p53 mutation (Gallion, Pieretti et al. 
1995; Lavarino, Pilotti et al. 2000; da Silva, de Castro Marcondes et al. 2010). 
We sought to determine if mTOR inhibition could enhance the efficacy of 
common chemotherapeutic agents used in bladder cancer. 
 
3.6. 1. Effect of chemotherapy agents on bladder cancer cells 
Bladder cancer cells (UM-UC-3, UM-UC-6, UM-UC-9, UM-UC-14, KU7 and 
T24) were treated with increasing doses of Cisplatin (0.1–100 µM) and 
incubated for up to 2 days. The cells were also treated with increasing doses of 
Gemcitabine (0.01- 10 µM) and incubated for up to 4 days.  The 
chemotherapeutic agents inhibited the growth of all bladder cancer cells tested 
in a dose-dependent manner (Fig. 3.6.1 and 3.6.2). For Cisplatin, all cell lines 
required a dose of 10 µM and above to achieve IC50, and T24 cells appeared 
relatively slower to respond to Cisplatin, compared to the other cell lines, 
especially at the first day of treatment (Fig. 3.6.1). UM-UC-6, UM-UC-9, UM-
UC-14 and T24 were sensitive to Gemcitabine (Fig. 3.6.2). However, UM-UC-
3 and KU7 required a higher dose (0.1 µM  and above) to achieve IC50, with 
UM-UC-3 being relatively more resistant compared to the other cell lines up 









Fig. 3.6.1. The inhibitory effects of Cisplatin on bladder cancer cell growth 
determined by crystal violet assays. UM-UC-3, UM-UC-6, UM-UC-9, UM-












Fig. 3.6.2. The inhibitory effects of Gemcitabine on bladder cancer cell growth 
determined by crystal violet assays. UM-UC-3, UM-UC-6, UM-UC-9, UM-









3.6. 2. Effect of combining chemotherapy agents and RAD001 on bladder 
cancer cells 
T24 cell line was treated with increasing doses of RAD001 and crystal violet 
assay was performed to determine its IC50, which was 10 nM (Fig 3.6.3). T24 
cell line was then treated with low dose Cisplatin (1 - 10 µM) in combination 
with RAD001 at increasing doses up to its IC50 dose, and incubated up to 3 
days. This was similarly performed for the cell lines UM-UC-3 and UM-UC-9. 
It was found that a low dose of RAD001 (1 nM) in combination with lower 
doses of Cisplatin (1 and 5 µM) was able to achieve a higher inhibitory effect 
on T24 cells compared to similar doses of Cisplatin alone (up to 5 µM) (Fig 
3.6.4A). Also, low doses of RAD001 (1 nM) when combined with low doses 
of Cisplatin (5 µM) was able to achieve an equivalent inhibitory effect to 
higher dose Cisplatin (10 µM) on T24 cells at 48 and 72 hours (Fig 3.6.4A). 
This observation of reduced dosage requirement for both RAD001 and 
Cisplatin when used in combination, to achieve similar inhibitory effects as 
higher Cisplatin doses, was similarly seen in UM-UC-9 cells (Fig 3.6.4C). The 
combination therapy also showed a similar trend in UM-UC-3 cells when low 
dose Cisplatin or Gemcitabine was combined with the IC50 dose of RAD001 
(Fig 3.5.4B and Fig 3.6.5). CompuSyn software analysis showed synergistic 
inhibitory effects between Cisplatin and RAD001 at 48 hours for UM-UC-9 
cells, and at 72 hours for UM-UC-3 and T24 cells. Similarly, CompuSyn 
software analysis showed synergistic inhibitory effects between Gemcitabine 
and RAD001 mainly at 48 hours for UM-UC-3 cells. Our results suggest a 
potential role for RAD001 in enhancing the effects of chemotherapeutic 
agents, and may allow for the use of lower doses of chemotherapy in the effort 






Fig. 3.6.3. The inhibitory effects of RAD001 on cell growth determined by 





























Fig 3.6.4. The inhibitory effects of Cisplatin + RAD001 on bladder cancer cell 
growth determined by crystal violet assays (left panel) and their corresponding 
combination index (CI) values based on CompuSyn analysis (right panel). (A) 
T24 [* p < 0.01, comparing Cisplatin with or without RAD001 (1 or 10 nM)], 
(B) UM-UC-3 [* p < 0.01, comparing Cisplatin with or without RAD001 (0.5 
or 1 nM)], and (C) UM-UC-9 [* p < 0.005, comparing Cisplatin with or 
without RAD001 (5 or 10 nM)] were treated with Cisplatin + RAD001 and 








Fig. 3.6.5. The inhibitory effects of Gemcitabine + RAD001 on bladder cancer 
cell growth determined by crystal violet assays (left panel) and their 
corresponding combination index (CI) values based on CompuSyn analysis 
(right panel). UM-UC-3 cells were treated with Gemcitabine + RAD001 and 
incubated for 3 days [* p < 0.0001, comparing Gemcitabine with or without 









3.7. Alternative form of mTOR therapy 
Systemic mTOR inhibition has the potential of patients developing clinical 
side effects such as thrombocytopenia, immunocompromised state, severe 
aphthous ulceration and stomatitis. Bladder cancer is amenable to local 
therapy in the form of intravesical therapy. With the aim of reducing systemic 
side effects, we investigated the possibility of an alternative form of mTOR 
therapy using SiRNA, with the hope of developing such intravesical treatment 
in future.  
 
3.7.1. SiRNA targeting mTOR: effects of bladder cancer cells 
UM-UC-3, UM-UC-6 and UM-UC-9 cells were transfected with small 
interfering RNA (SiRNA) targeting mTOR (SimTOR) and control non-
specific SiRNA (Csi) for 24 hours using the transfection reagent TransIT-TKO 
(Mirus, Madison, WI, USA) , and incubated for up to 5 days.  SimTOR 
inhibited the growth of UM-UC-3 and UM-UC-6 cells in a transient manner, 
with a partial loss of response seen 3 days after initial treatment (Fig. 3.7.1A, 
UM-UC-3 data not shown). UM-UC-9 cell line was however, not responsive 
to SimTOR treatment (Fig. 3.7.1B). Csi did not show any inhibitory effects on 
either cell line (Fig. 3.7.1). Retreatment of cells with SimTOR at 2 days after 
the initial therapy augmented the growth inhibition in UM-UC-6 but not in the 











Fig 3.7.1. The inhibitory effects of SimTOR on bladder cancer cell growth 
determined by crystal violet assays. (A) UM-UC-6 [* p < 0.05, comparing 
SimTOR with Csi (with or without redosing)] and (B) UM-UC-9, were treated 
with SimTOR and Csi transfection, and incubated for 3 and 5 days, with and 





3.7.2. Downstream effects of mTOR blockade by SiRNA  
To investigate the effects of SimTOR treatment on mTOR signaling, we used 
western blotting to analyze the levels of non-phosphorylated forms of mTOR 
and p70S6K, after a single 24-hour exposure of UM-UC-3, UM-UC-6 and 
UM-UC-9 cells to SimTOR and Csi. In UM-UC-3 and UM-UC-6 cell lines, 
the levels of p70S6K were reduced with SimTOR compared to Csi, which is 
what we expect when mTOR protein is blocked. However, only UM-UC-3 
showed reduction in the mTOR protein levels. It may be that the antibody 
detecting mTOR protein was not specific to the mTORC1. Another possibility 
is due to induction of immune effects eg. IFN by SiRNA itself, i.e. ‘‘off-
target’’ effects, which can possibly increase mTOR through PI3K activation 
(possibly via MAPK pathway) (Sui, Zhou et al. 2013). No effect of SimTOR 
was seen in UM-UC-9 cells both on mTOR protein levels and the downsteam 
non-phosphorylated form of p70S6K (Fig 3). Overall, the effects of SimTOR 
on the levels of these proteins in the mTOR signaling pathway did have some 
correlation with the relative sensitivity of each cell line to the growth 




Fig. 3.7.2. Western blot analysis of UM-UC-3, UM-UC-6 and UM-UC-9 cells 
























4.1. PART ONE 
 
Management of high-risk NMIBC patients remains one of most 
challenging problems in urologic practice. Advances have been made in recent 
years to improve upon the gold standard intravesical BCG immunotherapy, 
such as the use of maintenance BCG, combination of BCG plus interferon, and 
combination of BCG plus intravesical chemotherapy. Currently, the use of 
alternatives to BCG such as device-assisted intravesical chemotherapy and 
newer intravesical agents have not been shown to be better than BCG. Despite 
these advances, a significant number of patients still fail to respond to therapy, 
resulting in recurrence and progression to more invasive disease, which is 
potentially lethal. Therefore, whilst it is important to search for new therapies 
or strategies, it is also important to be able to identify patients who would 
either benefit from bladder preservation and BCG therapy, or those who 
should go on to early radical cystectomy in order to prevent progression of 
disease. The current use of clinico-pathological risk factors is still not 
sufficiently precise to help identify the most appropriate therapy for these 
patients. Recent studies focusing on genetic risk factors and BCG response 
may give some insight in the issue. 
 
It was noted in a murine model, that some mice were naturally resistant 
to mycobacteria, leishmania and salmonella infections, and that the Nramp1 
gene was identified to control such susceptibility in the mouse (Buu, Sanchez 
et al. 2000). Further work established that this gene was expressed by mature 
tissue macrophages during the innate phase of infection, by controlling the 





homolog NRAMP1 demonstrates a high degree of nucleotide sequence 
conservation and similar structure motifs of its protein with the mouse’s 
Nramp1, suggesting that their proteins have similar functions (Buu, Sanchez et 
al. 2000). The human NRAMP1 protein is localized to the late endocytic 
compartment of resting macrophages, and recruited to the membrane of the 
phagosome after phagocytosis (Gruenheid, Pinner et al. 1997). Functional 
studies show that the NRAMP1 protein alters the intra-lysosomal milieu 
harbouring mycobacterium tuberculosis (M. TB) to inhibit mycobacterial 
replication at the early stage of infection (Ma, Dou et al. 2002). Hence, a 
deficiency or decreased function in NRAMP1 would impair the body’s 
capacity to inhibit M. TB replication by macrophage, prior to the launch of 
acquired immunity specific to M. TB (Ma, Dou et al. 2002). Furthermore, the 
observation that human macrophages do not use nitric oxide (NO) synthase to 
generate NO for microbial killing suggests that NRAMP1 is involved by 
altering the macrophage activation rather than direct microbial killing 
(Schneemann, Schoedon et al. 1993; Buu, Sanchez et al. 2000). It was later 
found that NRAMP1 is a divalent cation (mainly iron) transporter which may 
restrict bacterial growth by controlling Fe2+ efflux in macrophages (Boelaert, 
Vandecasteele et al. 2007). During macrophage activation, NRAMP1 was also 
noted to exert quantitative effects in major histocompatibility complex class II 
expression and in processing of antigen for presentation to T cells (Boelaert, 
Vandecasteele et al. 2007; Stober, Brode et al. 2007). Thus NRAMP1 
functional deficiency may impair the body’s ability to inhibit M. TB 
replication, resulting in increased activation of the immune system (Ma, Dou 






In humans, it is shown that NRAMP1 gene polymorphisms play a role 
in susceptibility to tuberculosis and that this susceptibility varies with ethnicity 
(Bellamy, Ruwende et al. 1998; Gao, Fujishima et al. 2000; Ryu, Park et al. 
2000; Ma, Dou et al. 2002; Leung, Yip et al. 2007). The NRAMP1 D534N 
G:A genotype is significantly associated with increased susceptibility to 
tuberculosis infection in West African and Chinese patients (Bellamy, 
Ruwende et al. 1998; Leung, Yip et al. 2007). The A allele of the NRAMP1 
D543N genotype is present in a lower frequency in Caucasians (<0.01) 
compared to Africans (0.18) and Asians (0.1-0.18), and is postulated to be a 
reason why Caucasians are less susceptible to tuberculosis (Liu, Fujiwara et al. 
1995; Bellamy, Ruwende et al. 1998; Ryu, Park et al. 2000; Ma, Dou et al. 
2002). Allele 3 of the NRAMP1 (GT)n polymorphism has been found to be 
associated with protection against tuberculosis in human populations (Hoal, 
Lewis et al. 2004). The increased susceptibility of patients with D534N G:A 
genotype or non-allele 3 (GT)n genotypes to tuberculosis may be due to their 
decreased ability to eliminate mycobacteria. Although these polymorphisms 
are a disadvantage to patients with tuberculosis, it may present as an advantage 
to those who suffer from bladder cancer. We hypothesized that NMIBC 
patients with these genotypes possibly experience a sustained immunological 
response because of poor mycobacterial clearance when treated with 
intravesical BCG. Conversely, the BCG-resistant phenotype may result in too 
rapid elimination of mycobacteria, and a short-lived immune response. This 
hypothesis is supported by our findings that NMIBC patients with NRAMP1 





intravesical BCG. Murine studies support this hypothesis, as bladder tumours 
in Bcgs (susceptible) mice responded significantly better to intravesical BCG 
than in Bcgr mice (resistant) (Kadhim, Chin et al. 1997). Bcgs mice had 
decreased ability to control BCG multiplication early and have slow 
elimination of the bacteria later (Gros, Skamene et al. 1981; Buu, Sanchez et 
al. 2000).  
 
Decobert et al observed in their cohort of 67 Caucasian NMIBC 
patients treated with intravesical BCG (51/67 experienced recurrence), that the 
NRAMP1 D534N G:A genotype (in 8/67 patients) was associated with 
increased recurrence risk compared to the D534N G:G genotype (Decobert, 
Larue et al. 2006). However in our study, D534N G:G genotype was 
associated with increased recurrence risk instead. While the reason for the 
difference between the two studies is not certain, it should be noted that the 
populations studied were different. Furthermore, there was only a small 
number of patients who had the D534N G:A genotype in the Caucasian 
population (Decobert, Larue et al. 2006), limiting the reliability of the 
conclusions drawn. Another limitation of our study is that we had not shown 
the functional significance of this polymorphism, and future studies should 
further address this deficiency. 
 
It was shown that glutathione peroxidise-1 deficient mice had 
increased oxidative stress and neoplasms (Zhang, Ikeno et al. 2009). 
Increasing levels of oxidative stress correlate with advancing stage of human 





prevention and treatment (Badjatia, Satyam et al. 2009). The protein product 
of the hGPX1 Leu- allele is less responsive to selenium and results in 
decreased detoxification (Hu and Diamond 2003) Oxidation of the active site 
selenolate to selenenic acid is needed for glutathione peroxidases to catalyze 
the reduction of hydroperoxides (Nordberg and Arner 2001). Patients with the 
hGPX1 Pro/Leu (CT) genotype have a significantly increased risk of bladder 
cancer (Ichimura, Habuchi et al. 2004). Zhao et al had reported that the 
hGPX1 Pro/Leu (CT) genotype had a borderline protective role in bladder 
recurrence, in their cohort of 224 NMIBC patients, with the association being 
stronger in Caucasians (Zhao, Liang et al. 2005). However, this association 
was not specific to those treated with BCG, as only 57% (128/224) received 
intravesical BCG or other agents (Zhao, Liang et al. 2005). Furthermore, the 
study was retrospective in nature with likely inherent limitations such as 
heterogeneity in the study population and incompleteness of follow-up to 
detect recurrence. In our study, the hGPX1 CT genotype was instead 
associated with decreased recurrence time after intravesical BCG. Our group 
have previously shown that bladder cancer cells that internalize BCG had 
decreased cellular ROS (Pook, Esuvaranathan et al. 2002). Also, the 
combination of  BCG and antioxidant N-acetylcysteine caused  a greater 
reduction in ROS (anti-oxidant effect), and increased cytotoxicity in cancer 
cells (Pook, Esuvaranathan et al. 2002). This suggests that non-immunological 
effects of BCG may also determine anti-tumour response.  Further 
investigation of the relationship between the decreased detoxification ability of 
patients with hGPX1 Pro/Leu (CT) genotype and their poorer outcome with 






Our results show that the odds ratios for recurrence and the hazard 
ratios for time to recurrence for the NRAMP1 gene polymorphisms were 
relatively high compared to the traditional clinico-pathological risk factors 
such as tumour stage, grade and patient age, suggesting that they may have 
stronger relative predictive value.  However, this (especially for NRAMP1 
(GT)n) should be interpreted with caution as the sample size and the number 
of events, for each of the gene polymorphism were small. Further study with a 
larger sample size would be required to validate these findings. At the same 
time, it should be noted that many of the studies on gene polymorphisms 
influencing BCG response report low odds ratio (between 1.1-1.5). It is 
therefore likely that a combination of polymorphisms would yield a stronger 
influence than individual SNPs. In our study, the proportion of NMIBC 
patients with the D534N G:G genotype was relatively large. This could in part 
give some insight to the reasons why so many high risk patients fail despite 
adequate BCG therapy, but is also suggests that there are other mechanisms 
determining clinical outcome as well. We combined the risks of the significant 
genotypes, which yielded a higher predictive value than individual genotypes. 
This further strengthens the point that the reasons for BCG failure are multiple 
and the mechanism is likely to be highly complex, which could involve 
interplay of clinical, pathological, molecular and genetic factors. Future 
studies will require study of the relative weightage and combination of risk 






Our study also has limitations of being in a predominantly Chinese 
population. Hence, our results cannot be generalized to other ethnic groups. 
We were unable to analyse the effect of gender on treatment response as the 
number of female patients was too small. However, data analysis was adjusted 
for gender in both the uni- and multivariate analyses. Another limitation was 
that differences in the BCG regimens may influence conclusions drawn. In our 
study, the clinical outcomes of the two BCG only groups were similar, but the 
BCG plus interferon group had less recurrence. To factor in the therapeutic 
regimen, polymorphisms were analysed separately for BCG only groups and 
BCG plus interferon. The multivariate analysis performed included regimen 
type as a factor for analysis. Despite these limitations, we believe that the 
results provide insights into the possible role of NRAMP and hGPX1 
polymorphisms in the response to BCG therapy for NMIBC. 
 
In summary, our findings suggest that NRAMP1 and hGPX1 gene 
polymorphisms may correlate with response to BCG therapy in NMIBC 
patients. Studies with larger patient numbers are needed to validate these 












4.2. PART TWO 
Current management strategies for high risk NMIBC are not ideal. We 
explored the use of mTOR inhibition on bladder cancer cells to determine its 
therapeutic efficacy and effects. Being acutely aware of the problems and risks 
of cell line cross contamination, we started by authenticating our cell lines 
using a newer technique of STR profiling.  
 
Among the substrates in the PI3K-AKT-mTOR pathway, mTOR is 
thought to be one of the major targets of relevance to cancer therapy (Mansure, 
Nassim et al. 2009). Genetic variations on the PI3K-AKT-mTOR pathway in 
the form of PTEN mutations and several SNPs have been reported (Wu, Obata 
et al. 2004; Chen, Gu et al. 2010). It is also interesting to note that the 9q34 
loci of chromosome 9, contains the TSC1 tumour suppressor gene whose 
product regulates mTOR (Abraham, Pagano et al. 2007). As mentioned earlier 
(Tables 1.3 and 1.4), chromosome 9q34 deletions are a common feature in 
both muscle invasive and non-muscle invasive bladder cancers. This could 
suggest that mTOR inhibition may potentially be applied to all stages of 
bladder cancer. Phospho-mTOR expression was recently shown to be 
increased in 32% of human bladder cancers compared to non-cancerous 
bladder tissue, and activation of p-S6K was also seen in 25% of invasive 
human bladder cancers (which displayed altered p53 and PTEN expression) 
(Puzio-Kuter, Castillo-Martin et al. 2009; Makhlin, Zhang et al. 2010). Hansel 
et al had also shown that p-mTOR and p-PS6 expression were found to be high 
in both muscle-invasive and non-muscle-invasive bladder cancers (Hansel, 





mTOR pathway, may inhibit the growth of bladder cancer cells and we 
explored the various effects of mTOR inhibition on bladder cancer cells. A 
recent pre-clinical study had shown that mTOR inhibition by RAD001 has 
anti-proliferative activity in bladder cancer, supporting this hypothesis 
(Mansure, Nassim et al. 2009). In this study, we show that the inhibition of the 
mTOR pathway effectively reduces the growth of bladder cancer cells, in spite 
of the variations in genetic backgrounds of the bladder cancer cell lines. This 
presents further evidence that the PI3K-AKT-mTOR signaling pathway is 
important in bladder cancer and that mTOR may be used as a molecular target 
for bladder cancer therapy.  
 
Based on our results, the effect of mTOR inhibition by RAD001 and 
SimTOR, on bladder cancer cells in vitro and in vivo are summarized in 
Figures 4.1 and 4.2 respectively. Our in vitro results demonstrate that RAD001 
inhibits the growth of bladder cancer cells at concentrations that are 
physiologically safe in humans (Tabernero, Rojo et al. 2008). However, the 
response of bladder cancer cells to RAD001 in vitro was heterogeneous, with 
UM-UC-14 being the most sensitive cell line and UM-UC-9 being the least 
sensitive.  The IC50 of UM-UC-9 was approximately 20 times higher than in 
the UM-UC-3 and UM-UC-6 cell lines, and 100 times higher than in the UM-
UC-14 cell line respectively. The loss of the inhibitory effect of a single dose 
of RAD001 4 days after treatment was overcome by retreatment of cells on the 
third day following the first dose. This transient effect of RAD001 provided 







Fig. 4.1. The effect of RAD001 and SimTOR on bladder cancer cells in vitro. Sensitive cell lines refer to UM-UC-3, UM-UC-6 or UM-UC-14, 
and insensitive cell line refers to UM-UC-9. A dotted line is used when the association is not well understood. Downward pointing coloured 






Fig. 4.2. The effect of RAD001 on bladder cancer cells in vivo. Sensitive cell lines refer to UM-UC-3, UM-UC-6 or UM-UC-14, and insensitive 
cell line refers to UM-UC-9. A dotted line is used when the association is not well understood. Downward pointing coloured arrows mean 






Contrary to other reports (Dancey 2006; Mansure, Nassim et al. 2009), 
we observed that a single treatment of RAD001 did not cause a specific 
growth phase arrest in any of the cell lines we tested. Retreatment with 
RAD001 induced G0/G1 arrest in UM-UC-3 and UM-UC-6, but not in UM-
UC-9 cells, which are resistant to RAD001 in vitro (Fig. 4.1). Despite 
prolonged exposure by re-treatment every 3 days for 10 days, RAD001 still 
did not induce G0/G1 arrest in UM-UC-9 cells. Since MAP Kinase (MAPK) is 
known to regulate transcription of genes that are important for cell cycle, 
effects of the MAPK feedback loop with mTOR may contribute to the 
differential effects on cell cycle arrest seen in various cell lines (Fig. 4.1). The 
mTORC2 component of mTOR, which is known to regulate cell cycle 
progression, is usually not sensitive to inhibition by rapamycin and rapalogs 
(Fasolo and Sessa 2012). However, prolonged exposure with mTOR inhibitors 
may partially overcome this insensitivity of mTORC2 in some cell lines 
(Abraham and Gibbons 2007). The differences in the susceptibility to 
RAD001 in partially inhibiting mTORC2 in different cell lines may also 
contribute to the differential effects on cell cycle arrest seen in various cell 
lines (Fig. 4.1). 
 
mTOR inhibition has been reported to result in apoptosis in some types 
of cancer cells and selected models that lack p53 or p27 (Huang, Shu et al. 
2004). In contrast, we show that RAD001 induced non-apoptotic cell death in 
sensitive cell lines, even though there was variability of p53 expression in the 





known to occur, this was another possible mechanism of bladder cancer cell 
growth inhibition by RAD001 (Faivre, Kroemer et al. 2006), which we sought 
to explore. 
 
Like wild-type bladder cancer cells, the cell lines we tested have 
different alterations in the PTEN/AKT and p53 pathways. The UM-UC-3 cells 
have a PTEN deletion, constitutively active phosphorylated AKT, and mutated 
TP53; UM-UC-6 cells have wild-type PTEN and TP53; UM-UC-9 cells have 
reduced PTEN expression and active phosphorylated AKT; and UM-UC-14 
cells have wild-type PTEN and no phosphorylated AKT expression (Table 2.2) 
(Tanaka, Koul et al. 2000; Tanaka and Grossman 2003). The effect of mTOR 
inhibition on AKT activity has been reported to be variable; depending on the 
cell type, and inhibition of mTOR has led to increased activation, no change, 
or reduced phosphorylation of AKT after prolonged treatment (Sarbassov, Ali 
et al. 2006; Meric-Bernstam and Gonzalez-Angulo 2009). We show that 
RAD001 reduces the expression of phosphorylated AKT in the UM-UC-3- and 
UM-UC-9-derived tumours, where both cell lines constitutionally express 
phosphorylated AKT (Tables 2.2 and 3.3.1, and Fig. 4.2).  
 
This reduction in phosphorylated AKT expression was not seen in the 
RAD001-treated UM-UC-6–derived tumors, a cell line that has a normal 
PTEN/AKT pathway (Tables 1 and 2). Although it has been reported that in 
other tumours that PTEN and AKT status may correlate with the sensitivity of 
cell lines to mTOR inhibitors, we did not find this relationship to be present in 





variable PTEN/AKT status for our study (Yu, Toral-Barza et al. 2001; 
Mansure, Nassim et al. 2009). mTOR comprises two multiprotein complexes: 
mTOR complexes 1 and 2 (mTORC1 and mTORC2) (Meric-Bernstam and 
Gonzalez-Angulo 2009).  It is known that mTORC1 is rapamycin-sensitive 
and its activation results in phosphorylation of 4EBP1 and S6K1, while 
mTORC2 may be regulated by rapamycin to cause either AKT activation or 
inactivation (Meric-Bernstam and Gonzalez-Angulo 2009). The variable effect 
of RAD001 on phosphorylated AKT levels in different bladder cancer cell 
types could be due in part to the differential effects of mTOR inhibition on 
mTORC1 and mTORC2 in different cell lines. The complexity of the multiple 
pathways involved may be one of the reasons for not seeing a direct 
relationship between the PTEN/AKT status and effects of mTOR inhibition. 
 
Since mTOR inhibition was not seen to correlate with expression of 
upstream targets (PTEN and AKT), it is therefore likely that the variability of 
sensitivity and the transient nature of response of different cell types to single 
doses of RAD001 was mainly due to the differential effects of mTOR 
inhibition on downstream effectors. It is known that the downstream effectors 
of mTOR are 4E-BP1 and S6 kinase 1 (S6K1), both of which are regulators of 
protein translation (Dancey 2006; Mamane, Petroulakis et al. 2006). 
Activation of mTOR leads to phosphorylation of 4E-BP1, which prevents it 
from binding to eukaryotic initiation factor 4E (eIF4E). eIF4E is then free to 
bind to mRNA transcripts and other translation initiation complex proteins and 
activate cap-dependent translation (Hay and Sonenberg 2004; Dancey 2006; 





growth, phosphorylates ribosomal protein S6 and enhances the translation of 
5’-terminal oligopyrimidine tract mRNAs in some models (Meric-Bernstam 
and Gonzalez-Angulo 2009). S6K1 has also been reported to play a role in 
glucose homeostasis by phosphorylating insulin receptor substrate 1 and 
glycogen synthase kinase 3 and by regulating other factors such as eukaryotic 
initiation factor 4B, programmed cell death 4, eukaryotic elongation factor-2 
kinase, and S6K1 Aly/REF-like target (Dancey 2006; Meric-Bernstam and 
Gonzalez-Angulo 2009). Mansure et al recently suggested that the reduction of 
phosphorylation levels of S6 activation correlated with the sensitivity of 
bladder cancer cells to RAD001, and that S6 inhibition may reflect the 
sensitivity of these cells to mTOR inhibition (Mansure, Nassim et al. 2009). In 
our study, RAD001 reduced the expression of phosphorylated p70S6 kinase 
and phosphorylated 4E-BP1 in vitro in all cell lines tested (Fig. 3.2.6 and 4.1). 
However, we did not observe a correlation between S6 phosphorylation levels 
and sensitivity to mTOR inhibition by RAD001. One reason for the difference 
may be due to the fact that the panel of bladder cancer cell lines tested was 
different in both studies. The differential sensitivity of bladder cancer cells to 
mTOR inhibition may be due to a variety of other factors, such as variability 
of mTORC1 and mTORC2 response or activation / inhibition of other 
pathways in response to mTOR inhibition. It has been shown that mTORC1 
and S6K may be activated independent of mTOR, possibly through the MEK-
ERK signaling pathway (Lehman, Ledford et al. 2007; Winter, Fox et al. 
2010). It was also shown that RAD001 can activate MAPK, which is mediated 
by S6K-PI3K-RAS signaling, and that this feedback could be a cause of the 





2008). These complex relationships between mTOR and other pathways may 
account for differences in various cell lines’ sensitivity to RAD001 and the 
inability to reliably correlate expression of effectors such as S6K and response 
to mTOR inhibition. Such relationships deserve further investigation. 
Consistent with the reduced expression of phosphorylated p70S6 kinase and 
phosphorylated 4E-BP1 seen on the western blots, we demonstrated that 
RAD001 inhibited protein synthesis in all four cell lines (Fig. 4.1).  
 
Our in vivo data confirm that mTOR inhibition by RAD001 is effective 
in inhibiting the growth of UM-UC-3, UM-UC-6, and UM-UC-9 bladder 
cancer cells subcutaneously implanted into nude mice (Fig. 4.2). Although the 
bladder cancer cell lines we tested in vitro responded to RAD001 treatment 
with different sensitivities, this difference was not seen in vivo. We 
hypothesize that the differences in sensitivity to RAD001 between the cell 
lines in vitro and in vivo reflect the results of mTOR inhibition of alternate 
pathways such as the angiogenesis pathway, that are only functional in vivo. 
Although phosphorylated mTOR expression was decreased in all tested cell 
lines treated with RAD001 in vitro, this was not seen in vivo (Table 3.3.1., Fig. 
3.2.6, 4.1 and 4.2). There was either no change or slight increase in 
phosphorylated mTOR expression in UM-UC-3 and UM-UC-6 derived 
tumours. One possible explanation to account for the discrepancy is the lower 
sensitivity of mTORC2 to mTOR inhibition, which may be inhibited by 
prolonged multiple treatments in vivo, and could result in feedback changes in 
phosphorylated AKT, which in turn also affects phosphorylated mTOR 





and in vivo was not seen in RAD001 treated UM-UC-9 derived tumours, 
possibly because UM-UC-9 cells (possibly including its mTORC2) were 
comparatively less sensitive to mTOR inhibition (Table 3.3.1., Fig. 3.2.6, 4.1 
and 4.2). Consistent with the in vitro findings, phosphorylated p70S6K 
expression in RAD001-treated tumors was reduced in tumours derived from 
UM-UC-3 and UM-UC-6 cell lines (Fig. 4.2). However, contrary to our in 
vitro findings where expression was measured after a single RAD001 dose, 
UM-UC-9–derived tumours exhibited similar levels of phosphorylated 
p70S6K in RAD001- and control-treated tumours but had a significantly 
reduced mean vascular density (Table 3.3.1). Interestingly, VEGF expression 
was not different between the RAD001- and control-treated tumours in any of 
the three cell lines tested (Table 3.3.1). On the basis of these findings, we 
hypothesize that inhibition of protein synthesis through the S6K and 4E-BP1 
pathways, rather than inhibition of angiogenesis, appears to be the more 
important mechanism for bladder cancer cell growth inhibition in UM-UC-3 
and UM-UC-6 cells (Table 3.3.1, Fig. 3.3.2 and Fig. 4.2). However, in the 
UM-UC-9 cells, inhibition of angiogenesis, possibly through a non-VEGF–
related pathway, appears to play a dominant role (Fig. 4.2). Further work will 
be needed to investigate and verify this. 
 
Although the cell lines we tested had different genetic backgrounds, 
RAD001 was active against all cell lines tested both in vitro and in vivo, but 
the sensitivities of the different cell lines to RAD001 in vitro did not correlate 
with the in vivo results.  Our results suggest that the growth inhibitory action 





alterations in the AKT pathway or the AKT phosphorylation status.  
 
In summary, the mTOR inhibitor RAD001 inhibits protein synthesis 
and growth of bladder cancer cells in vitro at doses ranging from 0.1 nM to 
100 nM. Despite the heterogeneity of responses seen in vitro, RAD001 is 
effective in vivo, in part because of changes in angiogenesis. RAD001 
therefore affects tumour growth through different mechanisms, depending on 
the genotype of the bladder cancer cells. Limitations of the in vitro work 
include the small number of cell lines used, as responses of other cell lines to 
RAD001 may yield additional insights in the differential response to mTOR 
inhibition. Furthermore, there are potentially multiple mechanisms (such as 
differences in immunological responses in vivo eg. differential natural killer 
cells activity) for differences in sensitivity to mTOR inhibition that have yet to 
be tested. Despite these limitations, this work constitutes one of very few pre-















4.3. PART THREE 
 
Autophagy is a cellular pathway that has an important role of 
maintaining cellular homeostasis, by mediating the removal of dysfunctional 
or damaged organelles, which are digested and recycled for cell metabolism 
(Mizushima, Levine et al. 2008; Janku, McConkey et al. 2011). It represents a 
cell’s adaptation to triggers such as starvation and hypoxia (Mizushima, 
Levine et al. 2008; Janku, McConkey et al. 2011). It is increasingly recognized 
that autophagy has a role to maintain cancer cell survival during periods of 
metabolic stress but when unrestrained, can cause progressive consumption of 
cellular components and cell death (Janku, McConkey et al. 2011). Hence, 
although autophagy is primarily a protective process for the cell, it can also 
play a role in cell death (Mizushima, Levine et al. 2008).  
 
There is also now increasing evidence that mTORC1 acts as a major 
checkpoint in the pathway that regulates autophagy (Wullschleger, Loewith et 
al. 2006). In brief, when PI3K-AKT pathway is activated, through TSC 1 / 2 
protein it could result in mTORC1 mediated inhibition of autophagy. mTOR 
may regulate autophagy by associations with the ATG (autophagy-related) 
family of proteins (possibly ATG 1, 13 and 20 initially and would include 
other ATG proteins such as LC3 later) (Lee, Kim et al. 2007; Hosokawa, Hara 
et al. 2009; Janku, McConkey et al. 2011). The ROS-dependent ERK in the 
RAF-MEK-ERK pathway may also serve to increase autophagy in later stages. 
ROS has an important role in various pathological conditions and are thought 
to be involved in the pathogenesis of some types of cancers (Kim, Chu et al. 





regulate autophagy (Zhang, Kong et al. 2009). Interestingly, it is currently 
suggested that mTOR may be a key regulator of ROS in some cell types (Kim, 
Chu et al. 2005).   
 
Currently, there is very limited data on the role of PI3K-AKT-mTOR 
pathway on autophagy in bladder cancer, and it is still not known if direct 
mTOR inhibition would result in autophagy in bladder cancer cells. Having 
observed non-apoptotic death in the bladder cancer cells following RAD001 
therapy, we sought to determine if mTOR inhibition would result in 
autophagy, oxidative stress response and other membrane effects in bladder 
cancer cells.  
 
We performed TEM on a sensitive (UM-UC-6) and on a more resistant 
cell line (UM-UC-9), after treatment with RAD001. In UM-UC-6, there was a 
significant increase in the number autophagosomes seen in the treated cells 
compared with the non-treated cells (Fig. 4.1). This phenomenon was not seen 
in the more resistant UM-UC-9 cell line, although marked mitochondrial 
swelling was noted in most of the treated cells compared to controls. 
Autophagy is a dynamic process and it is known that static measurements can 
be misleading (Janku, McConkey et al. 2011). Furthermore, autophagic 
function is usually assumed based on autophagosome detection (Janku, 
McConkey et al. 2011). Currently, although quantitative electron microscopy 
is the most established method to measure autophagy, due to it being 
expensive and labour intensive, other methods are being used as well 





protein which is constitutively expressed in low levels in cells, using antibody 
based techniques such as immunoblotting or immunohistochemistry (Tanida, 
Ueno et al. 2008). As an alternative to direct LC3 detection, fluorescence 
detection of green fluorescence in GFP-LC3 can also be used (Klionsky, 
Abdalla et al. 2012). We therefore corroborated our observation of autophagy 
in RAD001 treated UM-UC-6 cells by showing the increase in GFP-LC3 
punctuation in cells, using fluorescence microscopy, after being transfected 
with a plasmid containing GFP-LC3, although direct detection of LC3 by 
immunoblotting techniques would be ideal. This was consistent with the 
current general understanding of the role of mTOR in regulating autophagy. 
mTOR inhibition is also known to induce autophagy in malignant glioma, 
breast cancer, ovarian cancer and non-small-cell lung cancer cell lines (Janku, 
McConkey et al. 2011). We used known autophagic inhibitors in an attempt to 
give further evidence of the induction of autophagic process in UM-UC-6 cells 
by RAD001. Pre-exposure plus concurrent treatment of known autophagic 
inhibitors 3-MA and LY294002, with RAD001 on UM-UC-6 cells was shown 
to prevent the development of autophagy. Similar to the TEM findings, we did 
not observe significant markers of autophagy in RAD001 treated UM-UC-9 
cells. Interestingly, mTOR inhibition did not result in any demonstrable 
autophagic process in a more resistant cell line even at high doses (UM-UC-9) 
and up to 72 hours of RAD001 treatment. It is also noted that UM-UC-9 has 
constitutionally activated AKT, which may result in inhibition of autophagy by 
mTORC1, while UM-UC-6 has constitutionally decreased AKT expression 
(Table 2.2). The reason for this observation is unknown. Although UM-UC-9 





to mTOR inhibition. One might postulate that perhaps mTOR inhibition by 
RAD001 was not able to overcome the inherent AKT-activated inhibitory 
effects on autophagy in UM-UC-9 cells.  
 
We also showed that with RAD001 treatment, UM-UC-6 cells had a 
significant decrease in intracellular ROS at 6 hours but no demonstrable 
difference in MMP compared to untreated cells (Fig. 3.4.6, 3.4.7 and 4.1). It is 
also noted that some types of ROS may not be measured by the CM-
H2DCFDA dye, and therefore not all types of ROS were accounted for. 
Autophagy when localized to areas of metabolic stress, has been found to have 
an important role of limiting DNA damage to cells caused by ROS (Janku, 
McConkey et al. 2011). Increased DNA instability leading to tumourigenesis 
has been previously shown in autophagy-deficient mammary cells (Karantza-
Wadsworth, Patel et al. 2007). Accumulation of ROS in malignant glioma cells 
was seen to cause changes in mitochondrial permeability with loss of MMP 
and disruption of mitochondrial dynamics, and induce autophagy through 
interference with AKT/mTOR signaling pathways (Zhang, Kong et al. 2009). 
Based on our observations, we hypothesize that induction of autophagy in 
UM-UC-6 cells may be protective rather than an actual mechanism of cell 
death, in part by limiting the accumulation of intracellular ROS and preventing 
changes in mitochondrial function, as part of a survival mechanism of the 
struggling cancer cells trying to cope with the metabolic stress of mTOR 
inhibition (Fig. 4.1). We then tested this hypothesis by treating UM-UC-6 cells 
with known autophagic inhibitors 3MA or Chloroquine in combination with 





combination therapy group compared to either RAD001 or autophagic 
inhibitor alone, especially when 3MA was used (seen separately in both the 
crystal violet assay and PI exclusion assay). This suggests that by inhibiting 
the autophagic process, UM-UC-6 cells had a decreased ability to cope with 
the increased metabolic stress of mTOR inhibition, leading to faster cell death 
than when being treated with RAD001 alone. Interestingly, we noticed an 
increased cell death from apoptosis when UM-UC-6 cells were treated with 
3MA plus RAD001 compared to 3MA alone (Fig. 4.1). Although this trend did 
not reach significance, it may suggest that apoptosis may be induced more 
than that accounted for when being treated with 3MA alone. However, other 
forms of cell death may have also increased. Thus, from our results, it would 
appear that the growth inhibitory effects of RAD001 on sensitive bladder 
cancer cells were mainly due to cell cycle arrest and non-apoptotic cell death 
(which could include autophagy) (Fig. 4.1). However, with the concomitant 
inhibition of autophagy (using autophagic inhibitors), apoptosis in these cells 
was increased by RAD001 treatment (Fig. 4.1). Investigating this observation 
with further work (such as performing annexin V assay or demonstrating 
caspase activation) to better detect the increase in apoptosis would be ideal. 
Recently, it has also been shown that simultaneous inhibition of autophagy and 
mTOR induced apoptosis in malignant fibrous histiocytoma and leukemia cell 
lines (Carayol, Vakana et al. 2010; Nakamura, Hitora et al. 2011).  
 
No difference in the intracellular ROS levels of UM-UC-9 cells was 
seen between RAD001 treated cells and controls. Despite mitochondrial 





differences in MMP was seen between RAD001 treatment and controls (Fig. 
4.1). Not surprisingly, neither the autophagic inhibitors nor its combination 
with RAD001 showed any significant increase in therapeutic efficacy. Taken 
together, mTOR inhibition in this more resistant cell line seems to induce 
different effects compared to the more sensitive cell lines. Further study is 
needed to determine the reasons for its differences. 
 
There has been much recent interest in autophagy due to its apparent 
paradoxical roles in cell survival and cell death, especially in cancer 
pathogenesis and cancer therapy. Many of the known autophagic inhibitors 
function by inhibiting lysosomal function and trafficking, which may in turn 
interfere with fusion of the lysosomes to autophagosomes (Janku, McConkey 
et al. 2011). A number of autophagic inhibitors are now being studied as anti-
tumour drugs (Kimura, Takabatake et al. 2013). However, it is still not 
completely proven that the effect of these drugs are specific to autophagic 
inhibition only or are there other effects on cellular functions such as another 
unknown effect on lysosomes (Kimura, Takabatake et al. 2013). From our 
results, it would suggest that autophagic inhibition may potentially enhance 
the therapeutic effect of mTOR inhibition with RAD001 in sensitive cell lines. 
This could be a potential new form of therapeutic strategy for bladder cancer, 
and further studies are needed to understand its effects and define its role. 
 
It has been reported in ovarian cancer cells with mutant p53 that AKT 
inhibition can sensitize these cells to chemotherapy agents such as Cisplatin 





Cisplatin and Gemcitabine, are being used in advanced muscle invasive 
bladder cancer and also in the form of intravesical therapy for NMIBC. 
Cisplatin causes DNA cross-links and lesions severe enough to lead to 
apoptosis (da Silva, de Castro Marcondes et al. 2010). It is perhaps one of the 
most potent anti-cancer agents known. Gemcitabine is a deoxycytidine analog, 
and its active metabolite can cause DNA replication blockage (Galmarini, 
Mackey et al. 2001). Cisplatin and Gemcitabine have been shown to induce 
G1-phase arrest and p53-independent apoptosis in a few bladder cancer cell 
lines (da Silva, de Castro Marcondes et al. 2010). We sought to determine if 
mTOR inhibition could enhance the efficacy of common chemotherapeutic 
agents used in bladder cancer. We first tested the efficacy of Cisplatin and 
Gemcitabine in a panel of bladder cancer cell lines with varying p53 and AKT 
status (Table 2.2). It is also known that T24 cells have mutated p53 (da Silva, 
de Castro Marcondes et al. 2010). From the in vitro data, we found that T24 
and UM-UC-3, both of which had p53 mutations, were relatively more 
resistant to Cisplatin and Gemcitabine respectively. Although several reports 
have shown that mutated p53 cancer cells are more resistant to Cisplatin than 
wild type cells by their increased susceptibility to chemotherapy induced 
apoptosis, other reports have suggested that responses to these agents may be 
independent of p53 status (Kartalou and Essigmann 2001; Kielb, Shah et al. 
2001; Fechner, Perabo et al. 2003; Watanabe, Nishiyama et al. 2004). When 
we combined Cisplatin therapy with mTOR inhibition, we found that we were 
able to achieve a higher growth inhibitory effect at 48 and 72 hours by 
combining the IC50 dose of RAD001 with Cisplatin at doses lower than its 





to Cisplatin. Interestingly, we were able to achieve this synergism by using 
RAD001 at a dose lower than its IC50 in UM-UC-9 cells, which are usually 
more resistant to RAD001. This suggests that there is a synergistic effect 
between RAD001 and Cisplatin at low concentrations in bladder cancer cell 
lines. Increasing the dose of RAD001 did not add to the synergistic effect with 
Cisplatin. This synergistic effect was not seen when higher doses of both drugs 
were used. When we combined RAD001 with Gemcitabine, we saw the same 
synergistic effect in UM-UC-3 cells, which is usually relatively more resistant 
to Gemcitabine. We were able to achieve a higher growth inhibition effect at 
48 and 72 hours by combining the IC50 dose of RAD001 with Gemcitabine at 
a dose lower than its IC50 for UM-UC-3 cells. Therefore, because clinically 
high concentrations of Cisplatin and Gemcitabine are very toxic to humans, 
being able to reduce the dose while maintaining efficacy of these 
chemotherapeutic agents are clinically relevant and can help to reduce side 
effects to patients. Our results suggest that mTOR inhibition has the potential 
role of sensitizing bladder cancer cells to enhance the efficacy of common 
chemotherapeutic agents used in bladder cancer. mTOR inhibition may also 
have the potential to overcome resistance to chemotherapy. Further studies to 
investigate the mechanism of cell death from this combination and to verify its 
increased efficacy in an animal model would be helpful.  
 
Systemic mTOR inhibition has clinical side effects such as 
thrombocytopenia, immunocompromised state, severe aphthous ulceration and 
stomatitis. Systemic chemotherapy is also very toxic. NMIBC is usually 





effects to patients. We sought to investigate the possibility of an alternative 
form of mTOR therapy using SiRNA, with the hope of developing intravesical 
therapy for NMIBC in future. Also, having shown a synergistic effect of 
mTOR inhibition and chemotherapy, developing an intravesical route of 
mTOR inhibition could pave the way to further evaluate the potential efficacy 
of intravesical mTOR inhibition plus chemotherapy for the treatment of high 
risk NMIBC and for those who fail intravesical BCG. Secondarily, we also 
sought to determine if the resistance to mTOR inhibition seen in UM-UC-9 
cells could be reduced by SiRNA knockdown. We showed that mTOR 
inhibition by SiRNA is feasible in sensitive cell lines and has similar efficacy 
compared to that seen when cells were treated with RAD001 (Fig. 4.1). 
However, SiRNA was not efficacious in the more resistant UM-UC-9 cells 
(Fig. 4.1). Downregulation of mTOR by SiRNA could be further confirmed 
using other techniques such as reverse transcription PCR to confirm loss of 
mRNA. Further study on the downstream effects and verification of treatment 
efficacy in an animal model would be needed. Here we show that SiRNA 
targeted against mTOR may have the potential to be evaluated as an 
intravesical therapeutic agent. 
  
4.4. Conclusions 
In summary, we show that NRAMP1 and hGPX1 gene polymorphisms 
may predict the response of intravesical BCG therapy in NMIBC patients. In 
the search for new therapy options for bladder cancer patients, we show that 
mTOR inhibition with RAD001 inhibits the growth of bladder cancer cells in 





seen in vitro, in part because of changes in angiogenesis. We also show that 
mTOR inhibition result in a broad range of metabolic and growth effects in 
bladder cancer cells, such as growth phase arrest after prolonged treatment in 
sensitive cell lines, cell death in the absence of apoptosis, changes in 
downstream signaling, inhibition of protein synthesis, reduction of 
angiogenesis in some tumours, induction of autophagy and changes in 
oxidative stress response in some cell lines (Fig. 4.1 and 4.2). We also 
demonstrated potential enhancement of mTOR inhibitory effects in sensitive 
bladder cancer cell lines by the combination treatment of RAD001 with 
autophagic inhibitors (Fig. 4.1). RAD001 was found to enhance the efficacy of 
common chemotherapeutic agents used in bladder cancer, such that reduced 
doses of chemotherapy could be used to achieve similar effects on bladder 
cancer cells. Finally, we also show efficacy of silencing mTOR using specific 
SiRNA on sensitive bladder cancer cells as a prelude to further investigations 
to determine its use intravesically for the treatment of NMIBC (Fig. 4.1). 
These findings suggest that mTOR is potentially a new therapeutic target for 
bladder cancer. This work, together with current limited but growing pre-
clinical evidence of the efficacy of mTOR inhibition in bladder cancer cells, 
suggest mTOR inhibition may have a future role in the treatment of selected 
human bladder urothelial cancers. Further studies are required to determine its 
exact role in bladder cancer therapy. 
 
4.5. Future Directions 
To address the limitations of sample size and ethnicity, we have 





successfully obtained a research grant (the National Medical Research Council 
grant). We aim to firstly validate our results in a larger patient cohort, secondly 
to determine if NRAMP1 gene polymorphisms could predict the clinical 
outcome in both Asian and Caucasian NMIBC patients who underwent BCG 
therapy, and finally, to compare its predictive value with other known gene 
polymorphisms (such as those found in DNA repair and cytokine genes) in 
order to determine the relative importance and possible synergistic predictive 
values on the clinical outcome of patients with NMIBC who underwent BCG 
therapy. We will also plan to employ next generation sequencing techniques to 
help further identify genetic polymorphisms in other genes that may predict 
BCG response. 
 
To further study the role of mTOR inhibition in bladder cancer therapy, 
we have also obtained a grant (NUS Academic Research Fund) to further 
characterize the downstream effects of silencing mTOR using specific SiRNA 
on bladder cancer cells, and to show its efficacy by performing intravesical 
transfection of SiRNA in an orthotopic murine bladder cancer model. We also 
secondarily aim to perform combination therapies with other intravesical 
agents. We are also planning to characterize further the mechanisms of 
synergism between mTOR inhibition and chemotherapeutic agents, with a 
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